0	0	1999-09-22	CD	O	B-NP	B-Num
0	1	12	CD	O	I-NP	B-Num
0	2	:	:	O	O	I-Num
0	3	03	CD	O	O	I-Num
0	4	SURFING	NNP	O	O	O
0	5	THE	DT	O	B-NP	O
0	6	HUMAN	NNP	O	I-NP	B-Animal
0	7	GENOME	NNP	O	I-NP	B-Jour
0	8	:	:	O	O	O
0	9	DATA	NNP	O	O	O
0	10	BASES	NNP	O	O	O
0	11	OF	IN	O	B-PP	O
0	12	GENETIC	NNP	O	B-NP	O
0	13	CODE	NNP	O	I-NP	O
0	14	ARE	VBP	O	B-VP	O
0	15	MOVING	NNP	O	B-NP	O
0	16	TO	TO	O	B-PP	O
0	17	THE	DT	O	B-NP	O
0	18	WEB	NNP	O	I-NP	O

1	0	SAN	NNP	O	O	O
1	1	FRANCISCO	NNP	O	O	O
1	2	_	NN	O	O	O
1	3	Call	VB	O	B-VP	O
1	4	it	PRP	O	B-NP	O
1	5	an	DT	O	B-NP	O
1	6	end-of-the-century	JJ	O	I-NP	O
1	7	business	NN	O	I-NP	O
1	8	case	NN	O	I-NP	O
1	9	study	NN	O	I-NP	O
1	10	.	.	O	O	O

2	0	Pangea	NNP	O	B-NP	B-Org
2	1	Systems	NNPS	O	I-NP	I-Org
2	2	Inc.	NNP	O	I-NP	I-Org
2	3	is	VBZ	O	B-VP	O
2	4	a	DT	O	B-NP	O
2	5	small	JJ	O	I-NP	O
2	6	but	CC	O	I-NP	O
2	7	leading	VBG	O	I-NP	O
2	8	company	NN	O	I-NP	B-OrgCorp
2	9	in	IN	O	B-PP	O
2	10	``	``	O	B-NP	O
2	11	bioinformaticsCOMMA	NN	O	I-NP	O
2	12	''	''	O	O	O
2	13	a	DT	O	B-NP	O
2	14	hot	JJ	O	I-NP	O
2	15	new	JJ	O	I-NP	O
2	16	field	NN	O	I-NP	O
2	17	that	WDT	O	B-NP	O
2	18	combines	VBZ	O	B-VP	O
2	19	the	DT	O	B-NP	O
2	20	two	CD	O	I-NP	B-Num
2	21	keystone	NN	O	I-NP	O
2	22	technologies	NNS	O	I-NP	O
2	23	of	IN	O	B-PP	O
2	24	the	DT	O	B-NP	O
2	25	1990s	CD	O	I-NP	B-Date
2	26	_	NN	O	I-NP	O
2	27	computing	NN	O	I-NP	O
2	28	and	CC	O	I-NP	O
2	29	biotechnology	NN	O	I-NP	O
2	30	.	.	O	O	O

3	0	But	CC	O	O	O
3	1	its	PP$	O	B-NP	O
3	2	products	NNS	O	I-NP	O
3	3	are	VBP	O	B-VP	O
3	4	expensive	JJ	O	O	O
3	5	and	CC	O	O	O
3	6	difficult	JJ	O	O	O
3	7	for	IN	O	O	O
3	8	mortals	NNS	O	B-NP	O
3	9	to	TO	O	B-VP	O
3	10	use	VB	O	I-VP	O
3	11	COMMA	COMMA	O	O	O
3	12	which	WDT	O	B-NP	O
3	13	limits	VBZ	O	B-VP	O
3	14	Pangea	NNP	O	B-NP	B-Loc
3	15	's	POS	O	B-NP	O
3	16	potential	JJ	O	I-NP	O
3	17	market	NN	O	I-NP	O
3	18	and	CC	O	O	O
3	19	reduces	VBZ	O	B-VP	O
3	20	the	DT	O	B-NP	O
3	21	prospects	NNS	O	I-NP	O
3	22	for	IN	O	B-PP	O
3	23	a	DT	O	B-NP	O
3	24	public	JJ	O	I-NP	O
3	25	stock	NN	O	I-NP	O
3	26	offering	NN	O	I-NP	O
3	27	.	.	O	O	O

4	0	What	WP	O	B-NP	O
4	1	to	TO	O	B-VP	O
4	2	do	VB	O	I-VP	O
4	3	?	.	O	O	O

5	0	This	DT	O	B-NP	O
5	1	being	VBG	O	B-VP	O
5	2	1999	CD	O	B-NP	B-Date
5	3	COMMA	COMMA	O	O	O
5	4	the	DT	O	B-NP	O
5	5	answer	NN	O	I-NP	O
5	6	if	IN	O	O	O
5	7	you	PRP	O	B-NP	O
5	8	are	VBP	O	B-VP	O
5	9	Pangea	NNP	O	B-NP	B-Loc
5	10	is	VBZ	O	B-VP	O
5	11	to	TO	O	B-PP	O
5	12	dot.com	NN	O	O	O
5	13	yourself	PRP	O	B-NP	O
5	14	.	.	O	O	O

6	0	This	DT	O	B-NP	O
6	1	week	NN	O	I-NP	O
6	2	Pangea	NNP	O	B-NP	B-Loc
6	3	COMMA	COMMA	O	O	O
6	4	which	WDT	O	B-NP	O
6	5	is	VBZ	O	B-VP	O
6	6	based	VBN	O	I-VP	O
6	7	in	IN	O	B-PP	O
6	8	Oakland	NNP	O	B-NP	B-LocCit
6	9	COMMA	COMMA	O	O	O
6	10	Calif.	NNP	O	B-NP	B-LocStat
6	11	COMMA	COMMA	O	O	O
6	12	intends	VBZ	O	B-VP	O
6	13	to	TO	O	I-VP	O
6	14	begin	VB	O	I-VP	O
6	15	a	DT	O	B-NP	O
6	16	shakedown	NN	O	I-NP	O
6	17	test	NN	O	I-NP	O
6	18	of	IN	O	B-PP	O
6	19	DoubleTwist.com	NNP	O	B-NP	O
6	20	COMMA	COMMA	O	O	O
6	21	a	DT	O	B-NP	O
6	22	new	JJ	O	I-NP	O
6	23	Web	NNP	O	I-NP	O
6	24	site	NN	O	I-NP	O
6	25	intended	VBD	O	B-VP	O
6	26	to	TO	O	I-VP	O
6	27	make	VB	O	I-VP	O
6	28	online	JJ	O	B-NP	O
6	29	genetic	JJ	O	I-NP	B-Medical
6	30	and	CC	O	I-NP	O
6	31	biological	JJ	O	I-NP	B-Jour
6	32	research	NN	O	I-NP	I-Jour
6	33	fast	RB	O	O	O
6	34	COMMA	COMMA	O	O	O
6	35	easy	JJ	O	O	O
6	36	and	CC	O	O	O
6	37	available	JJ	O	O	O
6	38	to	TO	O	B-PP	O
6	39	any	DT	O	B-NP	O
6	40	amateur	JJ	O	I-NP	O
6	41	or	CC	O	I-NP	O
6	42	professional	JJ	O	I-NP	O
6	43	biologist	NN	O	I-NP	B-ProfTitle
6	44	.	.	O	O	O

7	0	While	IN	O	O	O
7	1	the	DT	O	B-NP	O
7	2	test	NN	O	I-NP	O
7	3	phase	NN	O	I-NP	O
7	4	is	VBZ	O	B-VP	O
7	5	available	JJ	O	O	O
7	6	only	RB	O	O	O
7	7	to	TO	O	B-PP	O
7	8	faculty	NN	O	B-NP	O
7	9	and	CC	O	I-NP	O
7	10	students	NNS	O	I-NP	B-ProfTitle
7	11	at	IN	O	B-PP	O
7	12	Stanford	NNP	O	B-NP	B-OrgUniv
7	13	University	NNP	O	I-NP	I-OrgUniv
7	14	COMMA	COMMA	O	O	O
7	15	the	DT	O	B-NP	O
7	16	site	NN	O	I-NP	O
7	17	is	VBZ	O	B-VP	O
7	18	scheduled	VBN	O	I-VP	O
7	19	to	TO	O	I-VP	O
7	20	go	VB	O	I-VP	O
7	21	live	VB	O	O	O
7	22	for	IN	O	B-PP	O
7	23	general	JJ	O	B-NP	B-ProfTitle
7	24	use	NN	O	I-NP	O
7	25	in	IN	O	B-PP	O
7	26	December	NNP	O	B-NP	B-Date
7	27	.	.	O	O	O

8	0	The	DT	O	B-NP	O
8	1	DoubleTwist	JJ	O	I-NP	O
8	2	site	NN	O	I-NP	O
8	3	COMMA	COMMA	O	O	O
8	4	whose	WP$	O	B-NP	O
8	5	name	NN	O	I-NP	O
8	6	is	VBZ	O	B-VP	O
8	7	a	DT	O	B-NP	O
8	8	play	NN	O	I-NP	O
8	9	on	IN	O	B-PP	O
8	10	the	DT	O	B-NP	O
8	11	double-helix	JJ	O	I-NP	O
8	12	structure	NN	O	I-NP	O
8	13	of	IN	O	B-PP	O
8	14	DNA	NNP	O	B-NP	O
8	15	COMMA	COMMA	O	O	O
8	16	holds	VBZ	O	B-VP	O
8	17	the	DT	O	B-NP	O
8	18	near-term	JJ	O	I-NP	O
8	19	promise	NN	O	I-NP	O
8	20	of	IN	O	B-PP	O
8	21	lifting	VBG	O	B-VP	O
8	22	Pangea	NNP	O	B-NP	B-Loc
8	23	above	IN	O	B-PP	O
8	24	the	DT	O	B-NP	O
8	25	pack	NN	O	I-NP	O
8	26	of	IN	O	B-PP	O
8	27	competitors	NNS	O	B-NP	O
8	28	chasing	VBG	O	B-VP	O
8	29	the	DT	O	B-NP	O
8	30	business	NN	O	I-NP	O
8	31	opportunities	NNS	O	I-NP	O
8	32	in	IN	O	B-PP	O
8	33	bioinformatics	NNS	O	B-NP	B-Jour
8	34	.	.	O	O	O

9	0	But	CC	O	O	O
9	1	other	JJ	O	B-NP	O
9	2	companies	NNS	O	I-NP	B-OrgCorp
9	3	may	MD	O	B-VP	O
9	4	not	RB	O	I-VP	O
9	5	be	VB	O	I-VP	O
9	6	far	RB	O	O	O
9	7	behind	IN	O	O	O
9	8	.	.	O	O	O

10	0	And	CC	O	O	O
10	1	the	DT	O	B-NP	O
10	2	implications	NNS	O	I-NP	O
10	3	go	VBP	O	B-VP	O
10	4	beyond	IN	O	B-PP	O
10	5	the	DT	O	B-NP	O
10	6	interests	NNS	O	I-NP	O
10	7	of	IN	O	B-PP	O
10	8	professional	JJ	O	B-NP	O
10	9	biologists	NNS	O	I-NP	O
10	10	and	CC	O	I-NP	O
10	11	biotechnology	NN	O	I-NP	O
10	12	executives	NNS	O	I-NP	B-ProfTitle
10	13	.	.	O	O	O

11	0	As	IN	O	O	O
11	1	more	JJR	O	B-NP	O
11	2	of	IN	O	B-PP	O
11	3	the	DT	O	B-NP	O
11	4	arcane	JJ	O	I-NP	O
11	5	secrets	NNS	O	I-NP	O
11	6	of	IN	O	B-PP	O
11	7	genetics	NNS	O	B-NP	B-Jour
11	8	and	CC	O	O	I-Jour
11	9	molecular	JJ	O	B-NP	I-Jour
11	10	biology	NN	O	I-NP	I-Jour
11	11	become	VBP	O	B-VP	O
11	12	available	JJ	O	O	O
11	13	to	TO	O	B-PP	O
11	14	the	DT	O	B-NP	O
11	15	modemed	JJ	O	I-NP	O
11	16	masses	NNS	O	I-NP	O
11	17	COMMA	COMMA	O	O	O
11	18	some	DT	O	B-NP	O
11	19	industry	NN	O	I-NP	O
11	20	executives	NNS	O	I-NP	B-ProfTitle
11	21	foresee	VBP	O	B-VP	O
11	22	the	DT	O	B-NP	O
11	23	day	NN	O	I-NP	B-DayFest
11	24	when	WRB	O	O	O
11	25	an	DT	O	B-NP	O
11	26	educated	VBN	O	I-NP	O
11	27	consumer	NN	O	I-NP	O
11	28	might	MD	O	B-VP	O
11	29	take	VB	O	I-VP	O
11	30	a	DT	O	B-NP	O
11	31	CD-ROM	NN	O	I-NP	O
11	32	containing	VBG	O	B-VP	O
11	33	a	DT	O	B-NP	O
11	34	laboratory	NN	O	I-NP	O
11	35	's	POS	O	B-NP	O
11	36	rendering	NN	O	I-NP	O
11	37	of	IN	O	B-PP	O
11	38	his	PP$	O	B-NP	O
11	39	or	CC	O	I-NP	O
11	40	her	PP$	O	I-NP	O
11	41	genetic	JJ	O	I-NP	B-Medical
11	42	profile	NN	O	I-NP	O
11	43	COMMA	COMMA	O	O	O
11	44	and	CC	O	O	O
11	45	combine	VBP	O	B-VP	O
11	46	it	PRP	O	B-NP	O
11	47	with	IN	O	B-PP	O
11	48	a	DT	O	B-NP	O
11	49	Web	NNP	O	I-NP	O
11	50	surf	NN	O	I-NP	O
11	51	through	IN	O	B-PP	O
11	52	gene	NN	O	B-NP	O
11	53	libraries	NNS	O	I-NP	O
11	54	to	TO	O	B-VP	O
11	55	determine	VB	O	I-VP	O
11	56	the	DT	O	B-NP	O
11	57	person	NN	O	I-NP	O
11	58	's	POS	O	B-NP	O
11	59	predisposition	NN	O	I-NP	O
11	60	toward	IN	O	B-PP	O
11	61	adverse	JJ	O	B-NP	B-Medical
11	62	drug	NN	O	I-NP	B-Medical
11	63	reactions	NNS	O	I-NP	O
11	64	COMMA	COMMA	O	O	O
11	65	for	IN	O	B-PP	O
11	66	example	NN	O	B-NP	O
11	67	COMMA	COMMA	O	O	O
11	68	or	CC	O	O	O
11	69	for	IN	O	B-PP	O
11	70	Alzheimer	NNP	O	B-NP	B-Peop
11	71	's	POS	O	B-NP	O
11	72	disease	NN	O	I-NP	B-Medical
11	73	COMMA	COMMA	O	O	O
11	74	colon	NN	O	B-NP	O
11	75	cancer	NN	O	I-NP	B-Medical
11	76	or	CC	O	I-NP	O
11	77	other	JJ	O	I-NP	O
11	78	afflictions	NNS	O	I-NP	O
11	79	that	WDT	O	B-NP	O
11	80	might	MD	O	B-VP	O
11	81	eventually	RB	O	I-VP	O
11	82	be	VB	O	I-VP	O
11	83	treatable	JJ	O	O	O
11	84	through	IN	O	B-PP	O
11	85	gene	NN	O	B-NP	O
11	86	therapy	NN	O	I-NP	B-Medical
11	87	.	.	O	O	O

12	0	To	TO	O	B-VP	O
12	1	promote	VB	O	I-VP	O
12	2	its	PP$	O	B-NP	O
12	3	name	NN	O	I-NP	O
12	4	and	CC	O	I-NP	O
12	5	capabilities	NNS	O	I-NP	O
12	6	COMMA	COMMA	O	O	O
12	7	Pangea	NNP	O	B-NP	B-Loc
12	8	plans	NNS	O	B-VP	O
12	9	to	TO	O	I-VP	O
12	10	let	VB	O	I-VP	O
12	11	individuals	NNS	O	B-NP	O
12	12	who	WP	O	B-NP	O
12	13	make	VBP	O	B-VP	O
12	14	only	RB	O	B-NP	O
12	15	casual	JJ	O	I-NP	O
12	16	use	NN	O	I-NP	O
12	17	of	IN	O	B-PP	O
12	18	the	DT	O	B-NP	O
12	19	site	NN	O	I-NP	O
12	20	have	VBP	O	B-VP	O
12	21	access	NN	O	B-NP	O
12	22	to	TO	O	B-PP	O
12	23	its	PP$	O	B-NP	O
12	24	software	NN	O	I-NP	O
12	25	and	CC	O	I-NP	O
12	26	data	NNS	O	I-NP	O
12	27	base	VBP	O	B-VP	O
12	28	at	IN	O	B-PP	O
12	29	no	DT	O	B-NP	O
12	30	charge	NN	O	I-NP	O
12	31	.	.	O	O	O

13	0	Heavy	NNP	O	B-NP	O
13	1	users	NNS	O	I-NP	O
13	2	and	CC	O	I-NP	O
13	3	corporations	NNS	O	I-NP	B-OrgCorp
13	4	may	MD	O	B-VP	O
13	5	obtain	VB	O	I-VP	O
13	6	licenses	NNS	O	B-NP	O
13	7	to	TO	O	B-VP	O
13	8	pay	VB	O	I-VP	O
13	9	for	IN	O	B-PP	O
13	10	access	NN	O	B-NP	O
13	11	on	IN	O	B-PP	O
13	12	a	DT	O	B-NP	O
13	13	sliding	VBG	O	I-NP	O
13	14	fee	NN	O	I-NP	O
13	15	scale	NN	O	I-NP	O
13	16	_	NN	O	I-NP	O
13	17	which	WDT	O	B-NP	O
13	18	could	MD	O	B-VP	O
13	19	run	VB	O	I-VP	O
13	20	tens	NNS	O	B-NP	B-Num
13	21	of	IN	O	B-PP	O
13	22	thousands	NNS	O	B-NP	B-Num
13	23	of	IN	O	B-PP	O
13	24	dollars	NNS	O	B-NP	B-Money
13	25	a	DT	O	B-NP	O
13	26	year	NN	O	I-NP	O
13	27	COMMA	COMMA	O	O	O
13	28	but	CC	O	O	O
13	29	would	MD	O	B-VP	O
13	30	still	RB	O	I-VP	O
13	31	be	VB	O	I-VP	O
13	32	significantly	RB	O	O	O
13	33	less	JJR	O	O	O
13	34	than	IN	O	B-PP	O
13	35	the	DT	O	B-NP	O
13	36	$500COMMA000	NN	O	I-NP	B-Money
13	37	or	CC	O	I-NP	O
13	38	more	JJR	O	I-NP	O
13	39	that	IN	O	O	O
13	40	Pangea	NNP	O	B-NP	B-Loc
13	41	now	RB	O	O	O
13	42	charges	VBZ	O	B-VP	O
13	43	big	JJ	O	B-NP	O
13	44	pharmaceutical	JJ	O	I-NP	B-Medical
13	45	companies	NNS	O	I-NP	B-OrgCorp
13	46	to	TO	O	B-VP	O
13	47	buy	VB	O	I-VP	O
13	48	its	PP$	O	O	O
13	49	software	NN	O	O	O
13	50	outright	JJ	O	O	O
13	51	.	.	O	O	O

14	0	``	``	O	O	O
14	1	The	DT	O	B-NP	O
14	2	power	NN	O	I-NP	O
14	3	of	IN	O	B-PP	O
14	4	bioinformatics	NN	O	B-NP	B-Jour
14	5	has	VBZ	O	B-VP	O
14	6	been	VBN	O	I-VP	O
14	7	somewhat	RB	O	O	O
14	8	limited	JJ	O	O	O
14	9	to	TO	O	B-PP	O
14	10	those	DT	O	B-NP	O
14	11	who	WP	O	B-NP	O
14	12	could	MD	O	B-VP	O
14	13	afford	VB	O	I-VP	O
14	14	itCOMMA	NN	O	B-NP	O
14	15	''	''	O	O	O
14	16	said	VBD	O	B-VP	O
14	17	John	NNP	O	B-NP	B-Peop
14	18	Couch	NNP	O	I-NP	I-Peop
14	19	COMMA	COMMA	O	O	O
14	20	Pangea	NNP	O	B-NP	B-Loc
14	21	's	POS	O	B-NP	O
14	22	president	NN	O	I-NP	B-ProfTitle
14	23	and	CC	O	I-NP	O
14	24	chief	NN	O	I-NP	B-ProfTitle
14	25	executive	NN	O	I-NP	B-ProfTitle
14	26	COMMA	COMMA	O	O	O
14	27	who	WP	O	B-NP	O
14	28	was	VBD	O	B-VP	O
14	29	an	DT	O	B-NP	O
14	30	executive	NN	O	I-NP	B-ProfTitle
14	31	at	IN	O	B-PP	O
14	32	Apple	NNP	O	B-NP	B-OrgCorp
14	33	Computer	NNP	O	I-NP	I-OrgCorp
14	34	in	IN	O	B-PP	O
14	35	the	DT	O	B-NP	O
14	36	late	JJ	O	I-NP	O
14	37	1970s	CD	O	I-NP	B-Date
14	38	and	CC	O	O	O
14	39	early	JJ	O	B-NP	O
14	40	1980s	CD	O	I-NP	B-Date
14	41	.	.	O	O	O

15	0	``	``	O	O	O
15	1	I	PRP	O	B-NP	O
15	2	've	VBP	O	B-VP	O
15	3	been	VBN	O	I-VP	O
15	4	trying	VBG	O	I-VP	O
15	5	to	TO	O	I-VP	O
15	6	figure	VB	O	I-VP	O
15	7	out	IN	O	B-PP	O
15	8	how	WRB	O	O	O
15	9	to	TO	O	B-VP	O
15	10	empower	VBP	O	I-VP	O
15	11	the	DT	O	B-NP	O
15	12	scientist	NN	O	I-NP	B-ProfTitle
15	13	the	DT	O	B-NP	O
15	14	way	NN	O	I-NP	O
15	15	we	PRP	O	B-NP	O
15	16	did	VBD	O	B-VP	O
15	17	computer	NN	O	B-NP	O
15	18	users	NNS	O	I-NP	O
15	19	at	IN	O	B-PP	O
15	20	Apple	NNP	O	B-NP	B-Peop
15	21	in	IN	O	B-PP	O
15	22	the	DT	O	B-NP	O
15	23	early	JJ	O	I-NP	O
15	24	daysCOMMA	NN	O	I-NP	O
15	25	''	''	O	O	O
15	26	Couch	NNP	O	B-NP	B-Peop
15	27	said	VBD	O	B-VP	O
15	28	.	.	O	O	O

16	0	``	``	O	O	O
16	1	We	PRP	O	B-NP	O
16	2	saw	VBD	O	B-VP	O
16	3	the	DT	O	B-NP	O
16	4	opportunity	NN	O	I-NP	O
16	5	to	TO	O	B-VP	O
16	6	be	VB	O	I-VP	O
16	7	the	DT	O	B-NP	O
16	8	first	JJ	O	I-NP	B-Num
16	9	Web	NNP	O	I-NP	O
16	10	portal	NN	O	I-NP	O
16	11	that	IN	O	B-NP	O
16	12	enabled	VBD	O	B-VP	O
16	13	scientists	NNS	O	B-NP	B-ProfTitle
16	14	to	TO	O	B-VP	O
16	15	do	VB	O	I-VP	O
16	16	molecular	JJ	O	B-NP	B-Medical
16	17	research	NN	O	I-NP	O
16	18	.	.	O	O	O
16	19	''	''	O	O	O

17	0	Celera	NNP	O	B-NP	O
17	1	Genomics	NNP	O	I-NP	B-Jour
17	2	Group	NNP	O	I-NP	B-OrgCorp
17	3	is	VBZ	O	B-VP	O
17	4	another	DT	O	B-NP	O
17	5	company	NN	O	I-NP	B-OrgCorp
17	6	that	WDT	O	B-NP	O
17	7	has	VBZ	O	B-VP	O
17	8	said	VBD	O	I-VP	O
17	9	it	PRP	O	B-NP	O
17	10	will	MD	O	B-VP	O
17	11	offer	VB	O	I-VP	O
17	12	its	PP$	O	B-NP	O
17	13	bioinformatics	NN	O	I-NP	B-Jour
17	14	tools	NNS	O	I-NP	O
17	15	from	IN	O	B-PP	O
17	16	its	PP$	O	B-NP	O
17	17	Web	NNP	O	I-NP	O
17	18	site	NN	O	I-NP	O
17	19	COMMA	COMMA	O	O	O
17	20	although	IN	O	O	O
17	21	it	PRP	O	B-NP	O
17	22	has	VBZ	O	B-VP	O
17	23	not	RB	O	I-VP	O
17	24	specified	VBN	O	I-VP	O
17	25	a	DT	O	B-NP	O
17	26	launch	NN	O	I-NP	O
17	27	date	NN	O	I-NP	O
17	28	.	.	O	O	O

18	0	``	``	O	O	O
18	1	This	DT	O	B-NP	O
18	2	is	VBZ	O	B-VP	O
18	3	an	DT	O	B-NP	O
18	4	Internet	NN	O	I-NP	B-OrgCorp
18	5	companyCOMMA	NN	O	I-NP	O
18	6	''	''	O	O	O
18	7	said	VBD	O	B-VP	O
18	8	Craig	NNP	O	B-NP	B-Peop
18	9	Venter	NNP	O	I-NP	I-Peop
18	10	COMMA	COMMA	O	O	O
18	11	president	NN	O	B-NP	B-ProfTitle
18	12	and	CC	O	O	O
18	13	chief	NN	O	B-NP	B-ProfTitle
18	14	executive	NN	O	I-NP	B-ProfTitle
18	15	of	IN	O	B-PP	O
18	16	Celera	NNP	O	B-NP	O
18	17	COMMA	COMMA	O	O	O
18	18	a	DT	O	B-NP	O
18	19	unit	NN	O	I-NP	O
18	20	of	IN	O	B-PP	O
18	21	the	DT	O	B-NP	O
18	22	PE	NNP	O	I-NP	B-LocStat
18	23	Corp.	NNP	O	I-NP	B-OrgCorp
18	24	COMMA	COMMA	O	O	O
18	25	which	WDT	O	B-NP	O
18	26	is	VBZ	O	B-VP	O
18	27	based	VBN	O	I-VP	O
18	28	in	IN	O	B-PP	O
18	29	Rockville	NNP	O	B-NP	B-Loc
18	30	COMMA	COMMA	O	O	O
18	31	Md	NNP	O	B-NP	B-Loc
18	32	.	.	O	O	O

19	0	Scientists	NNS	O	B-NP	B-ProfTitle
19	1	and	CC	O	I-NP	O
19	2	nonscientists	NNS	O	I-NP	O
19	3	alike	RB	O	O	O
19	4	COMMA	COMMA	O	O	O
19	5	he	PRP	O	B-NP	O
19	6	said	VBD	O	B-VP	O
19	7	COMMA	COMMA	O	O	O
19	8	will	MD	O	B-VP	O
19	9	be	VB	O	I-VP	O
19	10	able	JJ	O	O	O
19	11	to	TO	O	B-VP	O
19	12	use	VB	O	I-VP	O
19	13	Celera	NNP	O	B-NP	B-Peop
19	14	's	POS	O	B-NP	O
19	15	tools	NNS	O	I-NP	O
19	16	to	TO	O	B-VP	O
19	17	gain	VB	O	I-VP	O
19	18	insights	NNS	O	B-NP	O
19	19	into	IN	O	B-PP	O
19	20	their	PP$	O	B-NP	O
19	21	genetic	JJ	O	I-NP	B-Medical
19	22	makeup	NN	O	I-NP	O
19	23	.	.	O	O	O

20	0	And	CC	O	O	O
20	1	as	IN	O	B-PP	O
20	2	catalogs	NNS	O	B-NP	O
20	3	of	IN	O	B-PP	O
20	4	common	JJ	O	B-NP	O
20	5	mutations	NNS	O	I-NP	O
20	6	correlated	VBD	O	B-VP	O
20	7	with	IN	O	B-PP	O
20	8	disease	NN	O	B-NP	B-Medical
20	9	become	VBP	O	B-VP	O
20	10	broadly	RB	O	O	O
20	11	available	JJ	O	O	O
20	12	COMMA	COMMA	O	O	O
20	13	he	PRP	O	B-NP	O
20	14	said	VBD	O	B-VP	O
20	15	COMMA	COMMA	O	O	O
20	16	individuals	NNS	O	B-NP	O
20	17	will	MD	O	B-VP	O
20	18	be	VB	O	I-VP	O
20	19	able	JJ	O	O	O
20	20	to	TO	O	B-VP	O
20	21	make	VB	O	I-VP	O
20	22	appropriate	JJ	O	B-NP	O
20	23	lifestyle	NN	O	I-NP	O
20	24	changes	NNS	O	I-NP	O
20	25	or	CC	O	I-NP	O
20	26	health-care	NN	O	I-NP	O
20	27	decisions	NNS	O	I-NP	O
20	28	.	.	O	O	O

21	0	``	``	O	O	O
21	1	You	PRP	O	B-NP	O
21	2	'll	MD	O	B-VP	O
21	3	be	VB	O	I-VP	O
21	4	able	JJ	O	O	O
21	5	to	TO	O	B-VP	O
21	6	log	VB	O	I-VP	O
21	7	on	IN	O	O	O
21	8	to	TO	O	B-PP	O
21	9	our	PP$	O	B-NP	O
21	10	data	JJ	O	I-NP	O
21	11	base	VBP	O	I-NP	O
21	12	and	CC	O	O	O
21	13	get	VBP	O	B-VP	O
21	14	information	NN	O	B-NP	O
21	15	about	IN	O	B-PP	O
21	16	yourselfCOMMA	NN	O	B-NP	O
21	17	''	''	O	O	O
21	18	Venter	NNP	O	B-NP	B-Peop
21	19	said	VBD	O	B-VP	O
21	20	.	.	O	O	O

22	0	``	``	O	O	O
22	1	Our	PP$	O	B-NP	O
22	2	ultimate	JJ	O	I-NP	O
22	3	customer	NN	O	I-NP	O
22	4	on	IN	O	B-PP	O
22	5	the	DT	O	B-NP	O
22	6	Internet	NN	O	I-NP	B-OrgCorp
22	7	is	VBZ	O	B-VP	O
22	8	individuals	NNS	O	B-NP	O
22	9	.	.	O	O	O
22	10	''	''	O	O	O

23	0	Bioinformatics	NNS	O	B-NP	B-Jour
23	1	is	VBZ	O	B-VP	O
23	2	a	DT	O	B-NP	O
23	3	field	NN	O	I-NP	O
23	4	that	WDT	O	B-NP	O
23	5	emerged	VBD	O	B-VP	O
23	6	from	IN	O	B-PP	O
23	7	the	DT	O	B-NP	O
23	8	Human	NNP	O	I-NP	B-Animal
23	9	Genome	NNP	O	I-NP	B-Jour
23	10	Project	NNP	O	I-NP	O
23	11	COMMA	COMMA	O	O	O
23	12	the	DT	O	B-NP	O
23	13	international	JJ	O	I-NP	O
23	14	quest	NN	O	I-NP	O
23	15	_	NN	O	I-NP	O
23	16	which	WDT	O	B-NP	O
23	17	began	VBD	O	B-VP	O
23	18	in	IN	O	B-PP	O
23	19	1988	CD	O	B-NP	B-Date
23	20	and	CC	O	O	O
23	21	is	VBZ	O	B-VP	O
23	22	expected	VBN	O	I-VP	O
23	23	to	TO	O	I-VP	O
23	24	be	VB	O	I-VP	O
23	25	concluded	VBN	O	I-VP	O
23	26	in	IN	O	B-PP	O
23	27	the	DT	O	B-NP	O
23	28	next	JJ	O	I-NP	O
23	29	two	CD	O	I-NP	B-Num
23	30	years	NNS	O	I-NP	B-Date
23	31	_	NN	O	I-NP	O
23	32	to	TO	O	B-VP	O
23	33	spell	VB	O	I-VP	O
23	34	out	IN	O	B-PP	O
23	35	the	DT	O	B-NP	O
23	36	precise	JJ	O	I-NP	O
23	37	sequence	NN	O	I-NP	O
23	38	of	IN	O	B-PP	O
23	39	the	DT	O	B-NP	O
23	40	three	CD	O	I-NP	B-Num
23	41	billion	CD	O	I-NP	B-Num
23	42	letters	NNS	O	I-NP	O
23	43	in	IN	O	B-PP	O
23	44	the	DT	O	B-NP	O
23	45	human	JJ	O	I-NP	B-Animal
23	46	genetic	JJ	O	I-NP	B-Medical
23	47	code	NN	O	I-NP	O
23	48	.	.	O	O	O

24	0	The	DT	O	B-NP	O
24	1	first	JJ	O	I-NP	B-Num
24	2	industry	NN	O	I-NP	O
24	3	spawned	VBD	O	B-VP	O
24	4	by	IN	O	B-PP	O
24	5	the	DT	O	B-NP	O
24	6	genome	NN	O	I-NP	B-Jour
24	7	project	NN	O	I-NP	O
24	8	was	VBD	O	B-VP	O
24	9	genomics	NN	O	B-NP	B-Jour
24	10	companies	NNS	O	I-NP	B-OrgCorp
24	11	COMMA	COMMA	O	O	O
24	12	which	WDT	O	B-NP	O
24	13	sell	VBP	O	B-VP	O
24	14	data	NNS	O	B-NP	O
24	15	bases	NNS	O	I-NP	O
24	16	of	IN	O	B-PP	O
24	17	individual	JJ	O	B-NP	O
24	18	genes	NNS	O	I-NP	O
24	19	whose	WP$	O	B-NP	O
24	20	sequences	NNS	O	I-NP	O
24	21	have	VBP	O	B-VP	O
24	22	already	RB	O	I-VP	O
24	23	been	VBN	O	I-VP	O
24	24	identified	VBN	O	I-VP	O
24	25	or	CC	O	O	O
24	26	are	VBP	O	B-VP	O
24	27	developing	VBG	O	I-VP	O
24	28	drugs	NNS	O	B-NP	O
24	29	aimed	VBN	O	B-VP	O
24	30	at	IN	O	B-PP	O
24	31	gene	NN	O	B-NP	O
24	32	targets	NNS	O	I-NP	O
24	33	.	.	O	O	O

25	0	As	IN	O	O	O
25	1	these	DT	O	B-NP	O
25	2	efforts	NNS	O	I-NP	O
25	3	began	VBD	O	B-VP	O
25	4	to	TO	O	I-VP	O
25	5	produce	VB	O	I-VP	O
25	6	vast	JJ	O	B-NP	O
25	7	amounts	NNS	O	I-NP	O
25	8	of	IN	O	B-PP	O
25	9	biological	JJ	O	B-NP	B-Medical
25	10	information	NN	O	I-NP	O
25	11	COMMA	COMMA	O	O	O
25	12	they	PRP	O	B-NP	O
25	13	needed	VBD	O	B-VP	O
25	14	powerful	JJ	O	B-NP	O
25	15	software	NN	O	I-NP	O
25	16	to	TO	O	B-VP	O
25	17	keep	VB	O	I-VP	O
25	18	track	NN	O	B-NP	O
25	19	and	CC	O	O	O
25	20	make	VBP	O	B-VP	O
25	21	sense	NN	O	B-NP	O
25	22	of	IN	O	B-PP	O
25	23	it	PRP	O	B-NP	O
25	24	all	DT	O	B-NP	O
25	25	.	.	O	O	O

26	0	And	CC	O	O	O
26	1	so	RB	O	O	O
26	2	COMMA	COMMA	O	O	O
26	3	in	IN	O	B-PP	O
26	4	the	DT	O	B-NP	O
26	5	early	JJ	O	I-NP	O
26	6	1990s	CD	O	I-NP	B-Date
26	7	COMMA	COMMA	O	O	O
26	8	bioinformatics	NNS	O	B-NP	B-Jour
26	9	was	VBD	O	B-VP	O
26	10	born	VBN	O	I-VP	O
26	11	as	IN	O	B-PP	O
26	12	a	DT	O	B-NP	O
26	13	tool	NN	O	I-NP	O
26	14	of	IN	O	B-PP	O
26	15	genomics	NNS	O	B-NP	B-Jour
26	16	.	.	O	O	O

27	0	While	IN	O	O	O
27	1	the	DT	O	B-NP	O
27	2	software	NN	O	I-NP	O
27	3	created	VBD	O	B-VP	O
27	4	by	IN	O	B-PP	O
27	5	the	DT	O	B-NP	O
27	6	government-funded	JJ	O	I-NP	O
27	7	labs	NNS	O	I-NP	O
27	8	like	IN	O	B-PP	O
27	9	the	DT	O	B-NP	O
27	10	Whitehead	NNP	O	I-NP	O
27	11	Institute	NNP	O	I-NP	O
27	12	at	IN	O	B-PP	O
27	13	the	DT	O	B-NP	O
27	14	Massachusetts	NNP	O	I-NP	B-OrgUniv
27	15	Institute	NNP	O	I-NP	I-OrgUniv
27	16	of	IN	O	B-PP	I-OrgUniv
27	17	Technology	NNP	O	B-NP	I-OrgUniv
27	18	is	VBZ	O	B-VP	O
27	19	in	IN	O	B-PP	O
27	20	the	DT	O	B-NP	O
27	21	public	JJ	O	I-NP	O
27	22	domain	NN	O	I-NP	O
27	23	COMMA	COMMA	O	O	O
27	24	with	IN	O	B-PP	O
27	25	intriguing	JJ	O	B-NP	O
27	26	names	NNS	O	I-NP	O
27	27	like	IN	O	B-PP	O
27	28	Blast	NNP	O	B-NP	B-Perform
27	29	and	CC	O	I-NP	O
27	30	Fasta	NNP	O	I-NP	B-Peop
27	31	COMMA	COMMA	O	O	O
27	32	the	DT	O	B-NP	O
27	33	genomics	NN	O	I-NP	B-Jour
27	34	companies	NNS	O	I-NP	B-OrgCorp
27	35	COMMA	COMMA	O	O	O
27	36	like	IN	O	B-PP	O
27	37	Human	NNP	O	B-NP	B-Animal
27	38	Genome	NNP	O	I-NP	B-Jour
27	39	Sciences	NNPS	O	I-NP	O
27	40	Inc.	NNP	O	I-NP	O
27	41	and	CC	O	O	O
27	42	Incyte	NNP	O	B-NP	O
27	43	Pharmaceuticals	NNP	O	I-NP	O
27	44	Inc.	NNP	O	I-NP	O
27	45	COMMA	COMMA	O	O	O
27	46	have	VBP	O	B-VP	O
27	47	kept	VBN	O	I-VP	O
27	48	their	PP$	O	B-NP	O
27	49	tools	NNS	O	I-NP	O
27	50	for	IN	O	B-PP	O
27	51	use	VBP	O	B-NP	O
27	52	by	IN	O	B-PP	O
27	53	themselves	PRP	O	B-NP	O
27	54	or	CC	O	O	O
27	55	their	PP$	O	O	O
27	56	licensed	VBD	O	O	O
27	57	partners	NNS	O	B-NP	O
27	58	.	.	O	O	O

28	0	That	DT	O	B-NP	O
28	1	is	VBZ	O	B-VP	O
28	2	Celera	NNP	O	B-NP	O
28	3	's	POS	O	B-NP	O
28	4	primary	JJ	O	I-NP	O
28	5	business	NN	O	I-NP	O
28	6	as	IN	O	O	O
28	7	well	RB	O	O	O
28	8	COMMA	COMMA	O	O	O
28	9	despite	IN	O	B-PP	O
28	10	Venter	NNP	O	B-NP	B-Peop
28	11	's	POS	O	B-NP	O
28	12	intent	NN	O	I-NP	O
28	13	to	TO	O	B-VP	O
28	14	offer	VB	O	I-VP	O
28	15	bioinformatics	NN	O	B-NP	B-Jour
28	16	services	NNS	O	I-NP	O
28	17	on	IN	O	B-PP	O
28	18	the	DT	O	B-NP	O
28	19	Web	NNP	O	I-NP	O
28	20	.	.	O	O	O

29	0	It	PRP	O	B-NP	O
29	1	was	VBD	O	B-VP	O
29	2	not	RB	O	O	O
29	3	long	RB	O	O	O
29	4	before	IN	O	B-PP	O
29	5	a	DT	O	B-NP	O
29	6	few	JJ	O	I-NP	O
29	7	entrepreneurs	NNS	O	I-NP	B-ProfTitle
29	8	and	CC	O	O	O
29	9	venture	NN	O	B-NP	O
29	10	capitalists	NNS	O	I-NP	O
29	11	saw	VBD	O	B-VP	O
29	12	an	DT	O	B-NP	O
29	13	opportunity	NN	O	I-NP	O
29	14	in	IN	O	B-PP	O
29	15	a	DT	O	B-NP	O
29	16	pure-play	JJ	O	I-NP	O
29	17	bioinformatics	NNS	O	I-NP	B-Jour
29	18	company	NN	O	I-NP	B-OrgCorp
29	19	COMMA	COMMA	O	O	O
29	20	which	WDT	O	B-NP	O
29	21	would	MD	O	B-VP	O
29	22	sell	VB	O	I-VP	O
29	23	not	RB	O	O	O
29	24	genes	NNS	O	B-NP	O
29	25	or	CC	O	I-NP	O
29	26	data	NNS	O	I-NP	O
29	27	COMMA	COMMA	O	O	O
29	28	but	CC	O	O	O
29	29	software	NN	O	B-NP	O
29	30	.	.	O	O	O

30	0	As	IN	O	B-PP	O
30	1	private	JJ	O	B-NP	O
30	2	companies	NNS	O	I-NP	B-OrgCorp
30	3	COMMA	COMMA	O	O	O
30	4	none	NN	O	B-NP	O
30	5	of	IN	O	B-PP	O
30	6	the	DT	O	B-NP	O
30	7	bioinformatics	NNS	O	I-NP	B-Jour
30	8	players	NNS	O	I-NP	O
30	9	publish	VBP	O	B-VP	O
30	10	revenue	NN	O	B-NP	O
30	11	figures	NNS	O	I-NP	O
30	12	COMMA	COMMA	O	O	O
30	13	but	CC	O	O	O
30	14	most	JJS	O	B-NP	O
30	15	say	VBP	O	B-VP	O
30	16	they	PRP	O	B-NP	O
30	17	are	VBP	O	B-VP	O
30	18	between	IN	O	B-PP	O
30	19	$5	NN	O	B-NP	B-Money
30	20	million	CD	O	I-NP	B-Num
30	21	and	CC	O	O	O
30	22	$10	NN	O	B-NP	B-Money
30	23	million	CD	O	I-NP	B-Num
30	24	in	IN	O	B-PP	O
30	25	annual	JJ	O	B-NP	O
30	26	sales	NNS	O	I-NP	O
30	27	COMMA	COMMA	O	O	O
30	28	and	CC	O	O	O
30	29	growing	VBG	O	B-VP	O
30	30	.	.	O	O	O

31	0	Indeed	RB	O	O	O
31	1	COMMA	COMMA	O	O	O
31	2	some	DT	O	B-NP	O
31	3	analysts	NNS	O	I-NP	B-ProfTitle
31	4	predict	VBP	O	B-VP	O
31	5	a	DT	O	B-NP	O
31	6	multibillion-dollar	JJ	O	I-NP	O
31	7	bioinformatics	NNS	O	I-NP	B-Jour
31	8	market	NN	O	I-NP	O
31	9	within	IN	O	B-PP	O
31	10	the	DT	O	B-NP	O
31	11	next	JJ	O	I-NP	O
31	12	10	CD	O	I-NP	B-Num
31	13	years	NNS	O	I-NP	I-Num
31	14	.	.	O	O	O

32	0	``	``	O	O	O
32	1	Bioinformatics	NNP	O	B-NP	B-Peop
32	2	is	VBZ	O	B-VP	O
32	3	not	RB	O	O	O
32	4	necessarily	RB	O	O	O
32	5	the	DT	O	B-NP	O
32	6	next	JJ	O	I-NP	O
32	7	wave	NN	O	I-NP	O
32	8	COMMA	COMMA	O	O	O
32	9	but	CC	O	O	O
32	10	the	DT	O	B-NP	O
32	11	glue	NN	O	I-NP	O
32	12	that	WDT	O	B-NP	O
32	13	holds	VBZ	O	B-VP	O
32	14	everything	NN	O	B-NP	O
32	15	togetherCOMMA	NN	O	I-NP	O
32	16	''	''	O	O	O
32	17	said	VBD	O	B-VP	O
32	18	Tim	NNP	O	B-NP	B-Peop
32	19	Wilson	NNP	O	I-NP	I-Peop
32	20	COMMA	COMMA	O	O	O
32	21	an	DT	O	B-NP	O
32	22	analyst	NN	O	I-NP	B-ProfTitle
32	23	with	IN	O	B-PP	O
32	24	S.G.	NNP	O	B-NP	O
32	25	Cowen	NNP	O	I-NP	O
32	26	.	.	O	O	O

33	0	``	``	O	O	O
33	1	If	IN	O	O	O
33	2	you	PRP	O	B-NP	O
33	3	don	VB	O	B-VP	O
33	4	't	NN	O	B-NP	O
33	5	get	VB	O	B-VP	O
33	6	that	DT	O	B-NP	O
33	7	part	NN	O	B-NP	O
33	8	right	NN	O	I-NP	O
33	9	COMMA	COMMA	O	O	O
33	10	it	PRP	O	B-NP	O
33	11	's	VBZ	O	B-VP	O
33	12	hard	JJ	O	O	O
33	13	to	TO	O	B-VP	O
33	14	realize	VB	O	I-VP	O
33	15	the	DT	O	B-NP	O
33	16	value	NN	O	I-NP	O
33	17	of	IN	O	B-PP	O
33	18	genomicsCOMMA	NN	O	B-NP	O
33	19	''	''	O	O	O
33	20	he	PRP	O	B-NP	O
33	21	said	VBD	O	B-VP	O
33	22	.	.	O	O	O

34	0	``	``	O	O	O
34	1	The	DT	O	B-NP	O
34	2	opportunity	NN	O	I-NP	O
34	3	is	VBZ	O	B-VP	O
34	4	something	NN	O	B-NP	O
34	5	obvious	JJ	O	O	O
34	6	to	TO	O	B-PP	O
34	7	anyone	NN	O	B-NP	O
34	8	who	WP	O	B-NP	O
34	9	speaks	VBZ	O	B-VP	O
34	10	to	TO	O	B-PP	O
34	11	pharmaceutical	JJ	O	B-NP	B-Medical
34	12	companies	NNS	O	I-NP	B-OrgCorp
34	13	.	.	O	O	O
34	14	''	''	O	O	O

35	0	With	IN	O	B-PP	O
35	1	the	DT	O	B-NP	O
35	2	DoubleTwist	JJ	O	I-NP	O
35	3	site	NN	O	I-NP	O
35	4	COMMA	COMMA	O	O	O
35	5	according	VBG	O	B-PP	O
35	6	to	TO	O	B-PP	O
35	7	Pangea	NNP	O	B-NP	B-Loc
35	8	COMMA	COMMA	O	O	O
35	9	a	DT	O	B-NP	O
35	10	researcher	NN	O	I-NP	B-ProfTitle
35	11	would	MD	O	B-VP	O
35	12	have	VB	O	I-VP	O
35	13	many	JJ	O	B-NP	O
35	14	of	IN	O	B-PP	O
35	15	the	DT	O	B-NP	O
35	16	same	JJ	O	I-NP	O
35	17	capabilities	NNS	O	I-NP	O
35	18	previously	RB	O	O	O
35	19	available	JJ	O	O	O
35	20	only	RB	O	O	O
35	21	to	TO	O	B-PP	O
35	22	the	DT	O	B-NP	O
35	23	company	NN	O	I-NP	B-OrgCorp
35	24	's	POS	O	B-NP	O
35	25	big	JJ	O	I-NP	O
35	26	corporate	JJ	O	I-NP	O
35	27	customers	NNS	O	I-NP	O
35	28	COMMA	COMMA	O	O	O
35	29	which	WDT	O	B-NP	O
35	30	include	VBP	O	B-VP	O
35	31	drug	NN	O	B-NP	B-Medical
35	32	companies	NNS	O	I-NP	B-OrgCorp
35	33	like	IN	O	B-PP	O
35	34	Bristol-Myers	NNP	O	B-NP	B-OrgCorp
35	35	Squibb	NNP	O	I-NP	I-OrgCorp
35	36	and	CC	O	O	O
35	37	Hoechst	NNP	O	B-NP	O
35	38	Marion	NNP	O	I-NP	B-Peop
35	39	Roussel	NNP	O	I-NP	I-Peop
35	40	.	.	O	O	O

36	0	After	IN	O	B-PP	O
36	1	logging	VBG	O	B-VP	O
36	2	on	IN	O	B-PP	O
36	3	to	TO	O	B-PP	O
36	4	the	DT	O	B-NP	O
36	5	DoubleTwist	JJ	O	I-NP	B-Loc
36	6	site	NN	O	I-NP	O
36	7	COMMA	COMMA	O	O	O
36	8	a	DT	O	B-NP	O
36	9	visitor	NN	O	I-NP	O
36	10	could	MD	O	B-VP	O
36	11	enter	VB	O	I-VP	O
36	12	a	DT	O	B-NP	O
36	13	partial	JJ	O	I-NP	O
36	14	sequence	NN	O	I-NP	O
36	15	of	IN	O	B-PP	O
36	16	a	DT	O	B-NP	O
36	17	gene	NN	O	I-NP	O
36	18	_	NN	O	O	O
36	19	some	DT	O	B-NP	O
36	20	combination	NN	O	I-NP	B-Medical
36	21	of	IN	O	B-PP	O
36	22	the	DT	O	B-NP	O
36	23	letters	NNS	O	I-NP	O
36	24	A	DT	O	O	O
36	25	COMMA	COMMA	O	O	O
36	26	C	NNP	O	B-NP	B-Loc
36	27	COMMA	COMMA	O	O	O
36	28	T	NNP	O	O	B-Org
36	29	and	CC	O	O	O
36	30	G	NNP	O	B-NP	B-Org
36	31	COMMA	COMMA	O	O	O
36	32	which	WDT	O	B-NP	O
36	33	make	VBP	O	B-VP	O
36	34	up	IN	O	B-PP	O
36	35	the	DT	O	B-NP	O
36	36	genetic	JJ	O	I-NP	B-Medical
36	37	alphabet	NN	O	I-NP	O
36	38	_	NN	O	I-NP	O
36	39	and	CC	O	O	O
36	40	then	RB	O	B-VP	O
36	41	search	VBP	O	I-VP	O
36	42	for	IN	O	B-PP	O
36	43	contiguous	JJ	O	B-NP	O
36	44	sequences	NNS	O	I-NP	O
36	45	that	WDT	O	B-NP	O
36	46	might	MD	O	B-VP	O
36	47	lead	VB	O	I-VP	O
36	48	to	TO	O	B-PP	O
36	49	a	DT	O	B-NP	O
36	50	full-length	JJ	O	I-NP	O
36	51	gene	NN	O	I-NP	O
36	52	.	.	O	O	O

37	0	Or	CC	O	O	O
37	1	if	IN	O	O	O
37	2	the	DT	O	B-NP	O
37	3	code	NN	O	I-NP	O
37	4	of	IN	O	B-PP	O
37	5	a	DT	O	B-NP	O
37	6	full-length	JJ	O	I-NP	O
37	7	gene	NN	O	I-NP	O
37	8	were	VBD	O	B-VP	O
37	9	known	VBN	O	I-VP	O
37	10	COMMA	COMMA	O	O	O
37	11	the	DT	O	B-NP	O
37	12	researcher	NN	O	I-NP	B-ProfTitle
37	13	could	MD	O	B-VP	O
37	14	ask	VB	O	I-VP	O
37	15	in	IN	O	B-PP	O
37	16	which	WDT	O	B-NP	O
37	17	tissues	NNS	O	B-NP	O
37	18	of	IN	O	B-PP	O
37	19	the	DT	O	B-NP	O
37	20	body	NN	O	I-NP	O
37	21	that	IN	O	B-NP	O
37	22	gene	NN	O	B-NP	O
37	23	is	VBZ	O	B-VP	O
37	24	found	VBD	O	I-VP	O
37	25	or	CC	O	I-VP	O
37	26	found	VBD	O	I-VP	O
37	27	only	RB	O	O	O
37	28	when	WRB	O	O	O
37	29	in	IN	O	B-PP	O
37	30	the	DT	O	B-NP	O
37	31	presence	NN	O	I-NP	O
37	32	of	IN	O	B-PP	O
37	33	cancer	NN	O	B-NP	B-Medical
37	34	.	.	O	O	O

38	0	To	TO	O	B-PP	O
38	1	the	DT	O	B-NP	O
38	2	extent	NN	O	I-NP	O
38	3	the	DT	O	B-NP	O
38	4	answer	NN	O	I-NP	O
38	5	is	VBZ	O	B-VP	O
38	6	available	JJ	O	O	O
38	7	in	IN	O	B-PP	O
38	8	the	DT	O	B-NP	O
38	9	scientific	JJ	O	I-NP	O
38	10	literature	NN	O	I-NP	O
38	11	COMMA	COMMA	O	O	O
38	12	including	VBG	O	B-PP	O
38	13	patent	NN	O	B-NP	O
38	14	filings	NNS	O	I-NP	O
38	15	COMMA	COMMA	O	O	O
38	16	the	DT	O	B-NP	O
38	17	software	NN	O	I-NP	O
38	18	would	MD	O	B-VP	O
38	19	retrieve	VB	O	I-VP	O
38	20	it	PRP	O	B-NP	O
38	21	and	CC	O	O	O
38	22	highlight	VBP	O	B-VP	O
38	23	relevant	JJ	O	B-NP	O
38	24	passages	NNS	O	I-NP	O
38	25	.	.	O	O	O

39	0	Other	JJ	O	B-NP	O
39	1	cross-referenced	JJ	O	I-NP	O
39	2	data	NNS	O	I-NP	O
39	3	might	MD	O	B-VP	O
39	4	include	VB	O	I-VP	O
39	5	notations	NNS	O	B-NP	O
39	6	on	IN	O	B-PP	O
39	7	what	WP	O	B-NP	O
39	8	biochemical	JJ	O	B-NP	B-Medical
39	9	materials	NNS	O	I-NP	O
39	10	are	VBP	O	B-VP	O
39	11	required	VBN	O	I-VP	O
39	12	for	IN	O	B-PP	O
39	13	working	VBG	O	B-VP	O
39	14	with	IN	O	B-PP	O
39	15	a	DT	O	B-NP	O
39	16	given	VBN	O	I-NP	O
39	17	gene	NN	O	I-NP	O
39	18	in	IN	O	B-PP	O
39	19	the	DT	O	B-NP	O
39	20	laboratory	NN	O	I-NP	O
39	21	.	.	O	O	O

40	0	Such	JJ	O	B-NP	O
40	1	are	VBP	O	B-VP	O
40	2	the	DT	O	B-NP	O
40	3	capabilities	NNS	O	I-NP	O
40	4	of	IN	O	B-PP	O
40	5	the	DT	O	B-NP	O
40	6	computational	JJ	O	I-NP	O
40	7	biology	NN	O	I-NP	O
40	8	that	WDT	O	B-NP	O
40	9	underlies	VBZ	O	B-VP	O
40	10	bioinformatics	NNS	O	B-NP	B-Jour
40	11	_	NN	O	I-NP	O
40	12	a	DT	O	B-NP	O
40	13	field	NN	O	I-NP	O
40	14	that	IN	O	O	O
40	15	Francis	NNP	O	B-NP	B-Peop
40	16	Collins	NNP	O	I-NP	I-Peop
40	17	COMMA	COMMA	O	O	O
40	18	director	NN	O	B-NP	B-ProfTitle
40	19	of	IN	O	B-PP	O
40	20	the	DT	O	B-NP	O
40	21	Human	NNP	O	I-NP	B-Org
40	22	Genome	NNP	O	I-NP	I-Org
40	23	Project	NNP	O	I-NP	I-Org
40	24	for	IN	O	B-PP	I-Org
40	25	the	DT	O	B-NP	I-Org
40	26	National	NNP	O	I-NP	I-Org
40	27	Institutes	NNPS	O	I-NP	I-Org
40	28	of	IN	O	B-PP	O
40	29	Health	NNP	O	B-NP	O
40	30	COMMA	COMMA	O	O	O
40	31	says	VBZ	O	B-VP	O
40	32	he	PRP	O	B-NP	O
40	33	now	RB	O	O	O
40	34	often	RB	O	O	O
40	35	counsels	VBZ	O	O	O
40	36	promising	JJ	O	B-NP	O
40	37	graduate	NN	O	I-NP	O
40	38	students	NNS	O	B-NP	B-ProfTitle
40	39	to	TO	O	B-VP	O
40	40	look	VB	O	I-VP	O
40	41	to	TO	O	B-PP	O
40	42	for	IN	O	O	O
40	43	career	NN	O	B-NP	O
40	44	opportunities	NNS	O	I-NP	O
40	45	.	.	O	O	O

41	0	``	``	O	O	O
41	1	I	PRP	O	B-NP	O
41	2	just	RB	O	O	O
41	3	think	VBP	O	B-VP	O
41	4	it	PRP	O	B-NP	O
41	5	is	VBZ	O	B-VP	O
41	6	going	VBG	O	I-VP	O
41	7	to	TO	O	I-VP	O
41	8	hit	VB	O	I-VP	O
41	9	us	PRP	O	B-NP	O
41	10	like	IN	O	B-PP	O
41	11	a	DT	O	B-NP	O
41	12	freight	NN	O	I-NP	O
41	13	train	NN	O	I-NP	O
41	14	and	CC	O	O	O
41	15	we	PRP	O	B-NP	O
41	16	really	RB	O	O	O
41	17	have	VBP	O	B-VP	O
41	18	too	RB	O	B-NP	O
41	19	small	JJ	O	I-NP	O
41	20	a	DT	O	I-NP	O
41	21	supply	NN	O	I-NP	O
41	22	of	IN	O	B-PP	O
41	23	expertise	NN	O	B-NP	O
41	24	in	IN	O	B-PP	O
41	25	that	IN	O	O	O
41	26	areaCOMMA	NN	O	B-NP	O
41	27	''	''	O	O	O
41	28	he	PRP	O	B-NP	O
41	29	said	VBD	O	B-VP	O
41	30	.	.	O	O	O

42	0	But	CC	O	O	O
42	1	there	EX	O	B-NP	O
42	2	has	VBZ	O	B-VP	O
42	3	been	VBN	O	I-VP	O
42	4	a	DT	O	B-NP	O
42	5	dichotomy	NN	O	I-NP	O
42	6	between	IN	O	B-PP	O
42	7	the	DT	O	B-NP	O
42	8	opportunity	NN	O	I-NP	O
42	9	and	CC	O	O	O
42	10	the	DT	O	B-NP	O
42	11	market	NN	O	I-NP	O
42	12	reality	NN	O	I-NP	O
42	13	for	IN	O	B-PP	O
42	14	Pangea	NNP	O	B-NP	B-Loc
42	15	and	CC	O	I-NP	O
42	16	competitors	NNS	O	I-NP	O
42	17	like	VBP	O	B-VP	O
42	18	Netgenics	NNP	O	B-NP	B-Peop
42	19	Inc.	NNP	O	I-NP	I-Peop
42	20	of	IN	O	B-PP	O
42	21	Cleveland	NNP	O	B-NP	B-LocCit
42	22	;	:	O	O	O
42	23	Informax	NNP	O	B-NP	O
42	24	Inc.	NNP	O	I-NP	O
42	25	of	IN	O	B-PP	O
42	26	Rockville	NNP	O	B-NP	B-Loc
42	27	COMMA	COMMA	O	O	O
42	28	Md.	NNP	O	B-NP	B-LocStat
42	29	;	:	O	O	O
42	30	Lion	NNP	O	B-NP	B-Animal
42	31	Bioscience	NNP	O	I-NP	B-Jour
42	32	AG	NNP	O	I-NP	B-OrgCorp
42	33	of	IN	O	B-PP	O
42	34	Heidelberg	NNP	O	B-NP	B-Loc
42	35	COMMA	COMMA	O	O	O
42	36	Germany	NNP	O	B-NP	B-LocCoun
42	37	;	:	O	O	O
42	38	Compugen	NNP	O	B-NP	O
42	39	Ltd.	NNP	O	I-NP	O
42	40	of	IN	O	B-PP	O
42	41	Tel	NNP	O	B-NP	O
42	42	Aviv	NNP	O	I-NP	O
42	43	;	:	O	O	O
42	44	the	DT	O	B-NP	O
42	45	Genomica	NNP	O	I-NP	B-OrgCorp
42	46	Corp.	NNP	O	I-NP	I-OrgCorp
42	47	of	IN	O	B-PP	O
42	48	Boulder	NNP	O	B-NP	B-Loc
42	49	COMMA	COMMA	O	O	O
42	50	Colo.	NNP	O	B-NP	O
42	51	;	:	O	O	O
42	52	and	CC	O	O	O
42	53	Molecular	NNP	O	B-NP	B-OrgCorp
42	54	Applications	NNPS	O	I-NP	I-OrgCorp
42	55	Group	NNP	O	I-NP	I-OrgCorp
42	56	of	IN	O	B-PP	O
42	57	Palo	NNP	O	B-NP	B-LocCit
42	58	Alto	NNP	O	I-NP	I-LocCit
42	59	COMMA	COMMA	O	O	O
42	60	Calif	NNP	O	B-NP	B-Loc
42	61	.	.	O	O	O

43	0	Most	JJS	O	B-NP	O
43	1	of	IN	O	B-PP	O
43	2	these	DT	O	B-NP	O
43	3	companies	NNS	O	I-NP	B-OrgCorp
43	4	are	VBP	O	B-VP	O
43	5	five	CD	O	B-NP	B-Num
43	6	years	NNS	O	I-NP	B-Date
43	7	old	JJ	O	O	O
43	8	or	CC	O	O	O
43	9	more	JJR	O	O	O
43	10	COMMA	COMMA	O	O	O
43	11	yet	RB	O	O	O
43	12	few	JJ	O	O	O
43	13	are	VBP	O	B-VP	O
43	14	profitable	JJ	O	O	O
43	15	.	.	O	O	O

44	0	Couch	NNP	O	B-NP	B-Loc
44	1	COMMA	COMMA	O	O	O
44	2	Pangea	NNP	O	B-NP	B-Loc
44	3	's	POS	O	B-NP	O
44	4	president	NN	O	I-NP	B-ProfTitle
44	5	COMMA	COMMA	O	O	O
44	6	said	VBD	O	B-VP	O
44	7	the	DT	O	B-NP	O
44	8	two	CD	O	I-NP	B-Num
44	9	hurdles	NNS	O	I-NP	O
44	10	to	TO	O	B-PP	O
44	11	expanding	VBG	O	B-VP	O
44	12	the	DT	O	B-NP	O
44	13	market	NN	O	I-NP	O
44	14	have	VBP	O	B-VP	O
44	15	been	VBN	O	I-VP	O
44	16	complexity	NN	O	B-NP	O
44	17	and	CC	O	I-NP	O
44	18	cost	NN	O	I-NP	O
44	19	.	.	O	O	O

45	0	Besides	IN	O	B-PP	O
45	1	the	DT	O	B-NP	O
45	2	$500COMMA000	NN	O	I-NP	B-Money
45	3	price	NN	O	I-NP	O
45	4	for	IN	O	B-PP	O
45	5	Pangea	NNP	O	B-NP	B-Loc
45	6	's	POS	O	B-NP	O
45	7	suite	NN	O	I-NP	O
45	8	of	IN	O	B-PP	O
45	9	software	NN	O	B-NP	O
45	10	programs	NNS	O	I-NP	O
45	11	COMMA	COMMA	O	O	O
45	12	a	DT	O	B-NP	O
45	13	suite	NN	O	I-NP	O
45	14	customer	NN	O	I-NP	O
45	15	must	MD	O	B-VP	O
45	16	make	VB	O	I-VP	O
45	17	a	DT	O	B-NP	O
45	18	comparable	JJ	O	I-NP	O
45	19	investment	NN	O	I-NP	O
45	20	in	IN	O	B-PP	O
45	21	hardware	NN	O	B-NP	O
45	22	.	.	O	O	O

46	0	And	CC	O	O	O
46	1	even	RB	O	O	O
46	2	though	IN	O	O	O
46	3	they	PRP	O	B-NP	O
46	4	have	VBP	O	B-VP	O
46	5	a	DT	O	B-NP	O
46	6	point-and-click	JJ	O	I-NP	O
46	7	graphical	JJ	O	I-NP	O
46	8	user	NN	O	I-NP	O
46	9	interface	NN	O	I-NP	O
46	10	COMMA	COMMA	O	O	O
46	11	like	IN	O	B-PP	O
46	12	any	DT	O	B-NP	O
46	13	Windows	NNP	O	I-NP	O
46	14	application	NN	O	I-NP	O
46	15	COMMA	COMMA	O	O	O
46	16	their	PP$	O	B-NP	O
46	17	sophistication	NN	O	I-NP	O
46	18	has	VBZ	O	B-VP	O
46	19	tended	VBN	O	I-VP	O
46	20	to	TO	O	I-VP	O
46	21	restrict	VB	O	I-VP	O
46	22	their	PP$	O	B-NP	O
46	23	use	NN	O	I-NP	O
46	24	to	TO	O	B-PP	O
46	25	bioinformatics	NNS	O	B-NP	B-Jour
46	26	specialists	NNS	O	I-NP	B-ProfTitle
46	27	within	IN	O	B-PP	O
46	28	large	JJ	O	B-NP	O
46	29	pharmaceutical	NN	O	I-NP	B-Medical
46	30	or	CC	O	I-NP	O
46	31	biotechnology	NN	O	I-NP	O
46	32	companies	NNS	O	I-NP	B-OrgCorp
46	33	COMMA	COMMA	O	O	O
46	34	not	RB	O	O	O
46	35	to	TO	O	B-PP	O
46	36	individual	JJ	O	B-NP	O
46	37	research	NN	O	I-NP	O
46	38	scientists	NNS	O	I-NP	B-ProfTitle
46	39	without	IN	O	B-PP	O
46	40	special	JJ	O	B-NP	O
46	41	training	NN	O	I-NP	O
46	42	.	.	O	O	O

47	0	In	IN	O	B-PP	O
47	1	moving	VBG	O	B-VP	O
47	2	to	TO	O	B-PP	O
47	3	the	DT	O	B-NP	O
47	4	Web	NNP	O	I-NP	B-Loc
47	5	COMMA	COMMA	O	I-NP	O
47	6	Pangea	NNP	O	I-NP	B-Loc
47	7	will	MD	O	B-VP	O
47	8	find	VB	O	I-VP	O
47	9	neighbors	NNS	O	B-NP	O
47	10	with	IN	O	B-PP	O
47	11	some	DT	O	B-NP	O
47	12	similar-sounding	JJ	O	I-NP	O
47	13	offerings	NNS	O	I-NP	O
47	14	.	.	O	O	O

48	0	This	DT	O	B-NP	O
48	1	week	NN	O	I-NP	O
48	2	COMMA	COMMA	O	O	O
48	3	HySeq	NNP	O	B-NP	B-Peop
48	4	Inc.	NNP	O	I-NP	I-Peop
48	5	COMMA	COMMA	O	O	O
48	6	a	DT	O	B-NP	O
48	7	genomics	NNS	O	I-NP	B-Jour
48	8	company	NN	O	I-NP	B-OrgCorp
48	9	in	IN	O	B-PP	O
48	10	Sunnyvale	NNP	O	B-NP	B-LocCit
48	11	COMMA	COMMA	O	O	O
48	12	Calif.	NNP	O	B-NP	B-LocStat
48	13	COMMA	COMMA	O	O	O
48	14	will	MD	O	B-VP	O
48	15	launch	VB	O	I-VP	O
48	16	GeneSolutions.com	NNP	O	B-NP	O
48	17	COMMA	COMMA	O	O	O
48	18	which	WDT	O	B-NP	O
48	19	will	MD	O	B-VP	O
48	20	sell	VB	O	I-VP	O
48	21	genes	NNS	O	B-NP	O
48	22	and	CC	O	O	O
48	23	genetic	JJ	O	B-NP	B-Medical
48	24	information	NN	O	I-NP	O
48	25	over	IN	O	B-PP	O
48	26	the	DT	O	B-NP	O
48	27	Web	NNP	O	I-NP	O
48	28	.	.	O	O	O

49	0	And	CC	O	O	O
49	1	there	EX	O	B-NP	O
49	2	are	VBP	O	B-VP	O
49	3	various	JJ	O	B-NP	O
49	4	Web	NNP	O	I-NP	O
49	5	sites	NNS	O	I-NP	O
49	6	COMMA	COMMA	O	O	O
49	7	for	IN	O	B-PP	O
49	8	example	NN	O	B-NP	O
49	9	COMMA	COMMA	O	O	O
49	10	that	IN	O	O	O
49	11	freely	RB	O	O	O
49	12	offer	NN	O	O	O
49	13	public-domain	NN	O	O	O
49	14	algorithms	NN	O	O	O
49	15	COMMA	COMMA	O	O	O
49	16	or	CC	O	O	O
49	17	mathematical	JJ	O	B-NP	O
49	18	formulas	NNS	O	I-NP	O
49	19	COMMA	COMMA	O	O	O
49	20	that	WDT	O	B-NP	O
49	21	can	MD	O	B-VP	O
49	22	perform	VB	O	I-VP	O
49	23	the	DT	O	B-NP	O
49	24	basic	JJ	O	I-NP	O
49	25	tasks	NNS	O	I-NP	O
49	26	of	IN	O	B-PP	O
49	27	bioinformatics	NNS	O	B-NP	B-Jour
49	28	.	.	O	O	O

50	0	These	DT	O	B-NP	O
50	1	include	VBP	O	B-VP	O
50	2	a	DT	O	B-NP	O
50	3	technique	NN	O	I-NP	O
50	4	called	VBD	O	B-VP	O
50	5	clustering	NN	O	B-NP	O
50	6	and	CC	O	I-NP	O
50	7	alignment	NN	O	I-NP	O
50	8	COMMA	COMMA	O	O	O
50	9	which	WDT	O	B-NP	O
50	10	pieces	NNS	O	B-NP	O
50	11	together	RB	O	O	O
50	12	full-length	JJ	O	B-NP	O
50	13	genes	NNS	O	I-NP	O
50	14	from	IN	O	B-PP	O
50	15	the	DT	O	B-NP	O
50	16	fragments	NNS	O	I-NP	O
50	17	spewed	VBD	O	B-VP	O
50	18	out	IN	O	O	O
50	19	by	IN	O	B-PP	O
50	20	so-called	JJ	O	O	O
50	21	automated	VBD	O	B-VP	O
50	22	sequencing	JJ	O	B-NP	O
50	23	machines	NNS	O	I-NP	O
50	24	that	WDT	O	B-NP	O
50	25	derive	VBP	O	B-VP	O
50	26	their	PP$	O	B-NP	O
50	27	data	NNS	O	I-NP	O
50	28	from	IN	O	B-PP	O
50	29	DNA	NNP	O	B-NP	B-Org
50	30	samples	NNS	O	I-NP	O
50	31	.	.	O	O	O

51	0	But	CC	O	O	O
51	1	these	DT	O	B-NP	O
51	2	public-domain	JJ	O	I-NP	O
51	3	tools	NNS	O	I-NP	O
51	4	tend	VBP	O	B-VP	O
51	5	to	TO	O	I-VP	O
51	6	be	VB	O	I-VP	O
51	7	difficult	JJ	O	O	O
51	8	to	TO	O	B-VP	O
51	9	use	VB	O	I-VP	O
51	10	COMMA	COMMA	O	O	O
51	11	and	CC	O	O	O
51	12	limited	JJ	O	O	O
51	13	in	IN	O	B-PP	O
51	14	their	PP$	O	B-NP	O
51	15	application	NN	O	I-NP	O
51	16	to	TO	O	B-PP	O
51	17	specific	JJ	O	B-NP	O
51	18	gene	NN	O	I-NP	O
51	19	data	NNS	O	I-NP	O
51	20	bases	NNS	O	I-NP	O
51	21	.	.	O	O	O

52	0	Pangea	NNP	O	B-NP	B-Loc
52	1	's	POS	O	B-NP	O
52	2	DoubleTwist	NNP	O	I-NP	O
52	3	COMMA	COMMA	O	O	O
52	4	by	IN	O	B-PP	O
52	5	contrast	NN	O	B-NP	O
52	6	COMMA	COMMA	O	O	O
52	7	will	MD	O	O	O
52	8	aggregate	JJ	O	B-NP	O
52	9	data	NNS	O	I-NP	O
52	10	from	IN	O	B-PP	O
52	11	multiple	JJ	O	B-NP	O
52	12	sources	NNS	O	I-NP	O
52	13	COMMA	COMMA	O	O	O
52	14	and	CC	O	O	O
52	15	then	RB	O	B-VP	O
52	16	make	VBP	O	I-VP	O
52	17	it	PRP	O	B-NP	O
52	18	available	JJ	O	O	O
52	19	using	VBG	O	B-VP	O
52	20	software	NN	O	O	O
52	21	agents	NNS	O	O	B-ProfTitle
52	22	_	NN	O	O	O
52	23	small	JJ	O	O	O
52	24	automated	VBD	O	B-VP	O
52	25	software	NN	O	B-NP	O
52	26	programs	NNS	O	I-NP	O
52	27	that	WDT	O	B-NP	O
52	28	will	MD	O	B-VP	O
52	29	scan	VB	O	I-VP	O
52	30	the	DT	O	B-NP	O
52	31	Web	NNP	O	I-NP	O
52	32	at	IN	O	B-PP	O
52	33	a	DT	O	B-NP	O
52	34	user	NN	O	I-NP	O
52	35	's	POS	O	B-NP	O
52	36	request	NN	O	I-NP	O
52	37	and	CC	O	O	O
52	38	return	VBP	O	B-VP	O
52	39	answers	NNS	O	B-NP	O
52	40	to	TO	O	B-PP	O
52	41	complex	JJ	O	B-NP	O
52	42	biological	JJ	O	I-NP	B-Medical
52	43	queries	NNS	O	I-NP	O
52	44	via	IN	O	B-PP	O
52	45	e-mail	NN	O	B-NP	O
52	46	.	.	O	O	O

53	0	Theses	NNS	O	B-NP	O
53	1	agents	NNS	O	I-NP	B-ProfTitle
53	2	can	MD	O	B-VP	O
53	3	update	VB	O	I-VP	O
53	4	information	NN	O	B-NP	O
53	5	as	IN	O	O	O
53	6	it	PRP	O	B-NP	O
53	7	becomes	VBZ	O	B-VP	O
53	8	available	JJ	O	O	O
53	9	COMMA	COMMA	O	O	O
53	10	suggest	VBP	O	B-VP	O
53	11	necessary	JJ	O	B-NP	O
53	12	laboratory	NN	O	I-NP	O
53	13	supplies	NNS	O	I-NP	O
53	14	and	CC	O	O	O
53	15	provide	VBP	O	B-VP	O
53	16	links	NNS	O	B-NP	O
53	17	to	TO	O	B-PP	O
53	18	vendors	NNS	O	B-NP	O
53	19	.	.	O	O	O

54	0	DoubleTwist	NN	O	B-NP	O
54	1	is	VBZ	O	B-VP	O
54	2	intended	VBN	O	I-VP	O
54	3	to	TO	O	I-VP	O
54	4	complement	VB	O	I-VP	O
54	5	rather	RB	O	O	O
54	6	than	IN	O	O	O
54	7	supplant	VB	O	B-VP	O
54	8	Pangea	NNP	O	B-NP	B-Loc
54	9	's	POS	O	B-NP	O
54	10	established	VBN	O	I-NP	O
54	11	software	NN	O	I-NP	O
54	12	suites	NNS	O	I-NP	O
54	13	.	.	O	O	O

55	0	But	CC	O	O	O
55	1	Couch	NNP	O	B-NP	B-Peop
55	2	said	VBD	O	B-VP	O
55	3	it	PRP	O	B-NP	O
55	4	was	VBD	O	B-VP	O
55	5	possible	JJ	O	O	O
55	6	that	IN	O	O	O
55	7	a	DT	O	B-NP	O
55	8	growing	VBG	O	I-NP	O
55	9	portion	NN	O	I-NP	O
55	10	of	IN	O	B-PP	O
55	11	the	DT	O	B-NP	O
55	12	company	NN	O	I-NP	B-OrgCorp
55	13	's	POS	O	B-NP	O
55	14	revenues	NNS	O	I-NP	O
55	15	would	MD	O	B-VP	O
55	16	come	VB	O	I-VP	O
55	17	from	IN	O	B-PP	O
55	18	the	DT	O	B-NP	O
55	19	Web	NNP	O	I-NP	O
55	20	rather	RB	O	O	O
55	21	than	IN	O	B-PP	O
55	22	packaged	VBN	O	B-NP	O
55	23	programs	NNS	O	I-NP	O
55	24	.	.	O	O	O

56	0	Rather	RB	O	O	O
56	1	than	IN	O	O	O
56	2	buy	VBP	O	B-VP	O
56	3	Pangea	NNP	O	B-NP	B-Loc
56	4	's	POS	O	B-NP	O
56	5	software	NN	O	I-NP	O
56	6	suite	NN	O	I-NP	O
56	7	for	IN	O	B-PP	O
56	8	$500COMMA000	NN	O	B-NP	B-Money
56	9	COMMA	COMMA	O	O	O
56	10	companies	NNS	O	B-NP	B-OrgCorp
56	11	or	CC	O	O	O
56	12	academic	JJ	O	B-NP	O
56	13	institutions	NNS	O	I-NP	O
56	14	could	MD	O	B-VP	O
56	15	spend	VB	O	I-VP	O
56	16	COMMA	COMMA	O	O	O
56	17	say	VBP	O	B-VP	O
56	18	$10COMMA000	NN	O	B-NP	B-Money
56	19	a	DT	O	B-NP	O
56	20	year	NN	O	I-NP	O
56	21	to	TO	O	B-VP	O
56	22	provide	VB	O	I-VP	O
56	23	each	DT	O	B-NP	O
56	24	user	NN	O	I-NP	O
56	25	access	NN	O	I-NP	O
56	26	to	TO	O	B-PP	O
56	27	these	DT	O	B-NP	O
56	28	programs	NNS	O	I-NP	O
56	29	over	IN	O	B-PP	O
56	30	the	DT	O	B-NP	O
56	31	Web	NNP	O	I-NP	O
56	32	.	.	O	O	O

57	0	Pangea	NNP	O	B-NP	B-Loc
57	1	's	POS	O	B-NP	O
57	2	competition	NN	O	I-NP	O
57	3	in	IN	O	B-PP	O
57	4	this	DT	O	B-NP	O
57	5	arena	NN	O	I-NP	O
57	6	is	VBZ	O	B-VP	O
57	7	companies	NNS	O	B-NP	B-OrgCorp
57	8	very	RB	O	O	O
57	9	much	RB	O	O	O
57	10	like	IN	O	B-PP	O
57	11	itself	PRP	O	B-NP	O
57	12	:	:	O	O	O
57	13	small	JJ	O	O	O
57	14	COMMA	COMMA	O	O	O
57	15	financed	VBN	O	B-VP	O
57	16	with	IN	O	B-PP	O
57	17	venture	NN	O	B-NP	O
57	18	capital	NN	O	I-NP	O
57	19	and	CC	O	O	O
57	20	possessing	VBG	O	B-VP	O
57	21	more	JJR	O	B-NP	O
57	22	programming	NN	O	I-NP	O
57	23	prowess	NN	O	I-NP	O
57	24	than	IN	O	B-PP	O
57	25	marketing	NN	O	B-NP	O
57	26	skills	NNS	O	I-NP	O
57	27	.	.	O	O	O

58	0	-LBR-	-LBR-	O	O	O
58	1	BEGIN	NNP	O	O	B-Org
58	2	OPTIONAL	NNP	O	O	I-Org
58	3	TRIM	NNP	O	O	I-Org
58	4	-RBR-	-RBR-	O	O	O

59	0	All	DT	O	B-NP	O
59	1	of	IN	O	B-PP	O
59	2	these	DT	O	B-NP	O
59	3	companies	NNS	O	I-NP	B-OrgCorp
59	4	are	VBP	O	B-VP	O
59	5	looking	VBG	O	I-VP	O
59	6	for	IN	O	B-PP	O
59	7	ways	NNS	O	B-NP	O
59	8	to	TO	O	B-VP	O
59	9	differentiate	VB	O	I-VP	O
59	10	themselves	PRP	O	B-NP	O
59	11	COMMA	COMMA	O	O	O
59	12	and	CC	O	O	O
59	13	while	IN	O	O	O
59	14	an	DT	O	B-NP	O
59	15	Internet	NN	O	I-NP	B-OrgCorp
59	16	presence	NN	O	I-NP	O
59	17	is	VBZ	O	B-VP	O
59	18	one	CD	O	B-NP	B-Num
59	19	way	NN	O	I-NP	O
59	20	to	TO	O	B-VP	O
59	21	do	VB	O	I-VP	O
59	22	that	IN	O	O	O
59	23	COMMA	COMMA	O	O	O
59	24	it	PRP	O	B-NP	O
59	25	is	VBZ	O	B-VP	O
59	26	by	IN	O	B-PP	O
59	27	no	DT	O	B-NP	O
59	28	means	VBZ	O	B-VP	O
59	29	the	DT	O	B-NP	O
59	30	only	JJ	O	I-NP	O
59	31	one	CD	O	I-NP	B-Num
59	32	.	.	O	O	O

60	0	For	IN	O	B-PP	O
60	1	example	NN	O	B-NP	O
60	2	COMMA	COMMA	O	O	O
60	3	Netgenics	NNP	O	B-NP	O
60	4	'	POS	O	B-NP	O
60	5	programs	NNS	O	I-NP	O
60	6	run	VBP	O	B-VP	O
60	7	on	IN	O	B-PP	O
60	8	corporate	JJ	O	B-NP	O
60	9	intranets	NNS	O	I-NP	O
60	10	COMMA	COMMA	O	O	O
60	11	rather	RB	O	O	O
60	12	than	IN	O	O	O
60	13	the	DT	O	B-NP	O
60	14	World	NNP	O	I-NP	B-OrgCorp
60	15	Wide	NNP	O	I-NP	I-OrgCorp
60	16	Web	NNP	O	I-NP	O
60	17	.	.	O	O	O

61	0	But	CC	O	O	O
61	1	they	PRP	O	B-NP	O
61	2	are	VBP	O	B-VP	O
61	3	built	VBN	O	I-VP	O
61	4	using	VBG	O	I-VP	O
61	5	Internet	NN	O	B-NP	B-OrgCorp
61	6	technology	NN	O	I-NP	O
61	7	like	IN	O	B-PP	O
61	8	the	DT	O	B-NP	O
61	9	Java	NNP	O	I-NP	O
61	10	programming	NN	O	I-NP	O
61	11	language	NN	O	I-NP	B-LangRace
61	12	so	IN	O	O	O
61	13	that	IN	O	O	O
61	14	they	PRP	O	B-NP	O
61	15	can	MD	O	B-VP	O
61	16	be	VB	O	I-VP	O
61	17	easily	RB	O	I-VP	O
61	18	adapted	VBN	O	I-VP	O
61	19	to	TO	O	B-PP	O
61	20	the	DT	O	B-NP	O
61	21	specific	NN	O	I-NP	O
61	22	needs	NNS	O	I-NP	O
61	23	of	IN	O	B-PP	O
61	24	different	JJ	O	B-NP	O
61	25	customers	NNS	O	I-NP	O
61	26	.	.	O	O	O

62	0	``	``	O	O	O
62	1	Pangea	NNP	O	B-NP	B-Peop
62	2	decided	VBD	O	B-VP	O
62	3	they	PRP	O	B-NP	O
62	4	would	MD	O	B-VP	O
62	5	come	VB	O	I-VP	O
62	6	up	IN	O	O	O
62	7	with	IN	O	B-PP	O
62	8	the	DT	O	B-NP	O
62	9	perfect	JJ	O	I-NP	O
62	10	schema	NN	O	I-NP	O
62	11	for	IN	O	B-PP	O
62	12	all	DT	O	B-NP	O
62	13	types	NNS	O	I-NP	O
62	14	of	IN	O	B-PP	O
62	15	drug	NN	O	B-NP	B-Medical
62	16	discovery	NN	O	I-NP	O
62	17	and	CC	O	O	O
62	18	put	VBD	O	B-VP	O
62	19	a	DT	O	O	O
62	20	nice	JJ	O	O	O
62	21	graphic	JJ	O	O	O
62	22	user	NN	O	O	O
62	23	interface	NN	O	O	O
62	24	on	IN	O	B-PP	O
62	25	itCOMMA	NN	O	B-NP	O
62	26	''	''	O	O	O
62	27	said	VBD	O	B-VP	O
62	28	Manuel	NNP	O	B-NP	B-Peop
62	29	J.	NNP	O	I-NP	I-Peop
62	30	Glynias	NNP	O	I-NP	I-Peop
62	31	COMMA	COMMA	O	O	O
62	32	president	NN	O	B-NP	B-ProfTitle
62	33	and	CC	O	O	O
62	34	chief	NN	O	B-NP	B-ProfTitle
62	35	executive	NN	O	I-NP	B-ProfTitle
62	36	of	IN	O	B-PP	O
62	37	Netgenics	NNP	O	B-NP	B-Org
62	38	COMMA	COMMA	O	O	O
62	39	which	WDT	O	B-NP	O
62	40	was	VBD	O	B-VP	O
62	41	founded	VBN	O	I-VP	O
62	42	in	IN	O	B-PP	O
62	43	1996	CD	O	B-NP	B-Date
62	44	.	.	O	O	O

63	0	``	``	O	O	O
63	1	We	PRP	O	B-NP	O
63	2	decided	VBD	O	B-VP	O
63	3	there	EX	O	B-NP	O
63	4	was	VBD	O	B-VP	O
63	5	no	DT	O	B-NP	O
63	6	perfect	JJ	O	I-NP	O
63	7	schema	NN	O	I-NP	O
63	8	because	IN	O	O	O
63	9	every	DT	O	B-NP	O
63	10	pharmaceutical	JJ	O	I-NP	B-Medical
63	11	company	NN	O	I-NP	B-OrgCorp
63	12	is	VBZ	O	B-VP	O
63	13	different	JJ	O	O	O
63	14	.	.	O	O	O
63	15	''	''	O	O	O

64	0	Netgenics	NNS	O	B-NP	O
64	1	did	VBD	O	B-VP	O
64	2	consider	VB	O	I-VP	O
64	3	a	DT	O	B-NP	O
64	4	Web-based	NNP	O	I-NP	O
64	5	electronic	JJ	O	I-NP	O
64	6	commerce	NN	O	I-NP	O
64	7	business	NN	O	I-NP	O
64	8	model	NN	O	I-NP	B-ProfTitle
64	9	COMMA	COMMA	O	O	O
64	10	but	CC	O	O	O
64	11	decided	VBD	O	B-VP	O
64	12	a	DT	O	B-NP	O
64	13	faster	JJR	O	I-NP	O
64	14	route	NN	O	I-NP	O
64	15	to	TO	O	B-PP	O
64	16	growth	NN	O	B-NP	O
64	17	was	VBD	O	B-VP	O
64	18	to	TO	O	O	O
64	19	bundle	VB	O	O	O
64	20	consulting	VBG	O	O	B-ProfTitle
64	21	services	NNS	O	O	O
64	22	with	IN	O	B-PP	O
64	23	custom	NN	O	B-NP	O
64	24	bioinformatics	NNS	O	I-NP	B-Jour
64	25	software	NN	O	I-NP	O
64	26	.	.	O	O	O

65	0	So	RB	O	O	O
65	1	far	RB	O	O	O
65	2	COMMA	COMMA	O	O	O
65	3	customers	NNS	O	B-NP	O
65	4	include	VBP	O	B-VP	O
65	5	Abbott	NNP	O	B-NP	B-OrgCorp
65	6	Laboratories	NNP	O	I-NP	I-OrgCorp
65	7	and	CC	O	O	O
65	8	Pfizer	NNP	O	B-NP	B-OrgCorp
65	9	.	.	O	O	O

66	0	``	``	O	O	O
66	1	We	PRP	O	B-NP	O
66	2	've	VBP	O	B-VP	O
66	3	very	RB	O	I-VP	O
66	4	much	RB	O	I-VP	O
66	5	targeted	VBN	O	I-VP	O
66	6	big	JJ	O	B-NP	O
66	7	pharma	NN	O	I-NP	O
66	8	and	CC	O	I-NP	O
66	9	biotechCOMMA	NN	O	I-NP	O
66	10	''	''	O	O	O
66	11	Glynias	NNP	O	B-NP	B-Peop
66	12	said	VBD	O	B-VP	O
66	13	.	.	O	O	O

67	0	``	``	O	O	O
67	1	They	PRP	O	B-NP	O
67	2	're	VBP	O	B-VP	O
67	3	the	DT	O	B-NP	O
67	4	only	RB	O	I-NP	O
67	5	ones	NNS	O	I-NP	O
67	6	who	WP	O	B-NP	O
67	7	can	MD	O	B-VP	O
67	8	afford	VB	O	I-VP	O
67	9	it	PRP	O	B-NP	O
67	10	COMMA	COMMA	O	O	O
67	11	and	CC	O	O	O
67	12	really	RB	O	O	O
67	13	the	DT	O	B-NP	O
67	14	only	JJ	O	I-NP	O
67	15	ones	NNS	O	I-NP	O
67	16	it	PRP	O	B-NP	O
67	17	makes	VBZ	O	B-VP	O
67	18	sense	NN	O	B-NP	O
67	19	for	IN	O	O	O
67	20	.	.	O	O	O

68	0	At	IN	O	B-PP	O
68	1	the	DT	O	B-NP	O
68	2	end	NN	O	I-NP	O
68	3	of	IN	O	B-PP	O
68	4	the	DT	O	B-NP	O
68	5	day	NN	O	I-NP	B-DayFest
68	6	you	PRP	O	B-NP	O
68	7	've	VBP	O	B-VP	O
68	8	got	VBD	O	I-VP	O
68	9	50	CD	O	B-NP	B-Num
68	10	big	JJ	O	I-NP	O
68	11	pharma	NN	O	I-NP	O
68	12	and	CC	O	I-NP	O
68	13	biotech	JJ	O	I-NP	O
68	14	companies	NNS	O	I-NP	B-OrgCorp
68	15	and	CC	O	O	O
68	16	100	CD	O	B-NP	B-Num
68	17	medium-sized	JJ	O	I-NP	O
68	18	ones	NNS	O	I-NP	O
68	19	.	.	O	O	O

69	0	It	PRP	O	B-NP	O
69	1	's	VBZ	O	B-VP	O
69	2	not	RB	O	O	O
69	3	a	DT	O	B-NP	O
69	4	big	JJ	O	I-NP	O
69	5	market	NN	O	I-NP	O
69	6	.	.	O	O	O
69	7	''	''	O	O	O

70	0	If	IN	O	O	O
70	1	the	DT	O	B-NP	O
70	2	market	NN	O	I-NP	O
70	3	is	VBZ	O	B-VP	O
70	4	small	JJ	O	O	O
70	5	COMMA	COMMA	O	O	O
70	6	creating	VBG	O	B-VP	O
70	7	a	DT	O	B-NP	O
70	8	big	JJ	O	I-NP	O
70	9	company	NN	O	I-NP	B-OrgCorp
70	10	requires	VBZ	O	B-VP	O
70	11	that	IN	O	O	O
70	12	each	DT	O	B-NP	O
70	13	sale	NN	O	I-NP	O
70	14	be	VB	O	B-VP	O
70	15	large	JJ	O	O	O
70	16	COMMA	COMMA	O	O	O
70	17	and	CC	O	O	O
70	18	Netgenics	NNP	O	B-NP	B-Org
70	19	bases	NNS	O	I-NP	O
70	20	its	PP$	O	B-NP	O
70	21	goals	NNS	O	I-NP	O
70	22	on	IN	O	B-PP	O
70	23	finding	VBG	O	B-VP	O
70	24	at	IN	O	O	O
70	25	least	JJS	O	O	O
70	26	20	CD	O	O	B-Num
70	27	customers	NNS	O	O	O
70	28	willing	JJ	O	O	O
70	29	to	TO	O	B-VP	O
70	30	pay	VB	O	I-VP	O
70	31	$5	NN	O	B-NP	B-Money
70	32	million	CD	O	I-NP	B-Num
70	33	annually	RB	O	O	O
70	34	for	IN	O	B-PP	O
70	35	its	PP$	O	B-NP	O
70	36	services	NNS	O	I-NP	O
70	37	.	.	O	O	O

71	0	Another	DT	O	B-NP	O
71	1	player	NN	O	I-NP	B-ProfTitle
71	2	COMMA	COMMA	O	O	O
71	3	Lion	NNP	O	B-NP	B-Peop
71	4	Bioscience	NNP	O	I-NP	I-Peop
71	5	COMMA	COMMA	O	O	O
71	6	takes	VBZ	O	B-VP	O
71	7	that	DT	O	B-NP	O
71	8	model	NN	O	I-NP	B-ProfTitle
71	9	a	DT	O	B-NP	O
71	10	step	NN	O	I-NP	O
71	11	further	RB	O	O	O
71	12	.	.	O	O	O

72	0	It	PRP	O	B-NP	O
72	1	recently	RB	O	O	O
72	2	announced	VBD	O	B-VP	O
72	3	a	DT	O	B-NP	O
72	4	deal	NN	O	I-NP	O
72	5	in	IN	O	B-PP	O
72	6	which	WDT	O	B-NP	O
72	7	it	PRP	O	B-NP	O
72	8	would	MD	O	B-VP	O
72	9	develop	VB	O	I-VP	O
72	10	new	JJ	O	B-NP	O
72	11	bioinformatics	NN	O	I-NP	B-Jour
72	12	systems	NNS	O	I-NP	O
72	13	and	CC	O	O	O
72	14	identify	VBP	O	B-VP	O
72	15	target	VBP	O	O	O
72	16	genes	NNS	O	B-NP	O
72	17	for	IN	O	B-PP	O
72	18	drug	NN	O	B-NP	B-Medical
72	19	development	NN	O	I-NP	O
72	20	by	IN	O	B-PP	O
72	21	Bayer	NNP	O	B-NP	B-OrgCorp
72	22	A.G.	NNP	O	I-NP	O
72	23	for	IN	O	B-PP	O
72	24	an	DT	O	B-NP	O
72	25	investment	NN	O	I-NP	O
72	26	estimated	VBD	O	B-VP	O
72	27	at	IN	O	B-PP	O
72	28	$100	NN	O	B-NP	B-Money
72	29	million	CD	O	I-NP	B-Num
72	30	.	.	O	O	O

73	0	The	DT	O	B-NP	O
73	1	figure	NN	O	I-NP	O
73	2	includes	VBZ	O	B-VP	O
73	3	an	DT	O	B-NP	O
73	4	up-front	JJ	O	I-NP	O
73	5	equity	NN	O	I-NP	O
73	6	stake	NN	O	I-NP	O
73	7	in	IN	O	B-PP	O
73	8	Lion	NNP	O	B-NP	B-Animal
73	9	as	RB	O	O	O
73	10	well	RB	O	O	O
73	11	as	IN	O	O	O
73	12	fees	NNS	O	B-NP	O
73	13	for	IN	O	B-PP	O
73	14	use	VBP	O	B-NP	O
73	15	of	IN	O	B-PP	O
73	16	Lion	NNP	O	B-NP	B-Animal
73	17	's	POS	O	B-NP	O
73	18	existing	VBG	O	I-NP	O
73	19	information	NN	O	I-NP	B-Jour
73	20	systems	NNS	O	I-NP	I-Jour
73	21	COMMA	COMMA	O	O	O
73	22	research	NN	O	B-NP	O
73	23	and	CC	O	I-NP	O
73	24	set-up	JJ	O	I-NP	O
73	25	costs	NNS	O	I-NP	O
73	26	for	IN	O	B-PP	O
73	27	a	DT	O	B-NP	O
73	28	new	JJ	O	I-NP	O
73	29	subsidiary	NN	O	I-NP	O
73	30	to	TO	O	B-VP	O
73	31	be	VB	O	I-VP	O
73	32	based	VBN	O	I-VP	O
73	33	in	IN	O	B-PP	O
73	34	Cambridge	NNP	O	B-NP	B-Loc
73	35	COMMA	COMMA	O	O	O
73	36	Mass.	NNP	O	B-NP	B-Loc
73	37	COMMA	COMMA	O	O	O
73	38	and	CC	O	O	O
73	39	royalties	NNS	O	B-NP	O
73	40	on	IN	O	B-PP	O
73	41	drugs	NNS	O	B-NP	O
73	42	developed	VBN	O	B-VP	O
73	43	from	IN	O	B-PP	O
73	44	the	DT	O	B-NP	O
73	45	gene	NN	O	I-NP	O
73	46	targets	NNS	O	I-NP	O
73	47	identified	VBN	O	B-VP	O
73	48	at	IN	O	B-PP	O
73	49	the	DT	O	B-NP	O
73	50	subsidiary	NN	O	I-NP	O
73	51	.	.	O	O	O

74	0	Lion	NNP	O	B-NP	B-Animal
74	1	calls	VBZ	O	B-VP	O
74	2	its	PP$	O	O	O
74	3	concept	NN	O	O	O
74	4	iBiology	NN	O	O	O
74	5	COMMA	COMMA	O	O	O
74	6	and	CC	O	O	O
74	7	like	VBP	O	B-VP	O
74	8	Netgenics	NNP	O	B-NP	O
74	9	'	POS	O	B-NP	O
74	10	approach	NN	O	I-NP	O
74	11	COMMA	COMMA	O	O	O
74	12	it	PRP	O	B-NP	O
74	13	uses	VBZ	O	B-VP	O
74	14	intranets	NNS	O	B-NP	O
74	15	rather	RB	O	B-PP	O
74	16	than	IN	O	I-PP	O
74	17	the	DT	O	B-NP	O
74	18	Internet	NN	O	I-NP	B-OrgCorp
74	19	.	.	O	O	O

75	0	``	``	O	O	O
75	1	It	PRP	O	B-NP	O
75	2	goes	VBZ	O	B-VP	O
75	3	far	RB	O	O	O
75	4	beyond	IN	O	B-PP	O
75	5	the	DT	O	B-NP	O
75	6	usual	JJ	O	I-NP	O
75	7	gene	NN	O	I-NP	O
75	8	sequence	NN	O	I-NP	O
75	9	analysis	NN	O	I-NP	B-Medical
75	10	softwareCOMMA	NN	O	I-NP	O
75	11	''	''	O	O	O
75	12	said	VBD	O	B-VP	O
75	13	Claus	NNP	O	B-NP	B-Peop
75	14	Kermoser	NNP	O	I-NP	I-Peop
75	15	COMMA	COMMA	O	O	O
75	16	Lion	NNP	O	B-NP	B-Peop
75	17	's	POS	O	B-NP	O
75	18	vice	NN	O	I-NP	B-ProfTitle
75	19	president	NN	O	I-NP	I-ProfTitle
75	20	for	IN	O	B-PP	O
75	21	corporate	JJ	O	B-NP	O
75	22	development	NN	O	I-NP	O
75	23	.	.	O	O	O

76	0	``	``	O	O	O
76	1	We	PRP	O	B-NP	O
76	2	crawl	NN	O	O	O
76	3	further	JJ	O	O	O
76	4	up	IN	O	B-PP	O
76	5	the	DT	O	B-NP	O
76	6	value	NN	O	I-NP	O
76	7	chain	NN	O	I-NP	O
76	8	to	TO	O	B-VP	O
76	9	include	VB	O	I-VP	O
76	10	the	DT	O	B-NP	O
76	11	chemical	NN	O	I-NP	B-Medical
76	12	side	NN	O	I-NP	O
76	13	COMMA	COMMA	O	O	O
76	14	and	CC	O	O	O
76	15	also	RB	O	O	O
76	16	pharmacological	JJ	O	B-NP	B-Medical
76	17	and	CC	O	I-NP	O
76	18	toxicology	NN	O	I-NP	B-Jour
76	19	data	NNS	O	I-NP	O
76	20	.	.	O	O	O

77	0	It	PRP	O	B-NP	O
77	1	's	VBZ	O	B-VP	O
77	2	not	RB	O	O	O
77	3	just	RB	O	B-NP	O
77	4	a	DT	O	B-NP	O
77	5	software	NN	O	I-NP	O
77	6	package	NN	O	I-NP	O
77	7	COMMA	COMMA	O	I-NP	O
77	8	tools	NNS	O	I-NP	O
77	9	and	CC	O	I-NP	O
77	10	data	NNS	O	I-NP	O
77	11	;	:	O	O	O
77	12	it	PRP	O	B-NP	O
77	13	's	VBZ	O	B-VP	O
77	14	a	DT	O	B-NP	O
77	15	solution	NN	O	I-NP	O
77	16	for	IN	O	B-PP	O
77	17	pharmaceuticals	NNS	O	B-NP	O
77	18	research	NN	O	I-NP	O
77	19	data	NNS	O	I-NP	O
77	20	management	NN	O	I-NP	O
77	21	.	.	O	O	O
77	22	''	''	O	O	O

78	0	In	IN	O	B-PP	O
78	1	fact	NN	O	B-NP	O
78	2	COMMA	COMMA	O	O	O
78	3	Lion	NNP	O	B-NP	B-Peop
78	4	is	VBZ	O	B-VP	O
78	5	actually	RB	O	O	O
78	6	a	DT	O	B-NP	O
78	7	hybrid	NN	O	I-NP	O
78	8	of	IN	O	B-PP	O
78	9	pure-play	JJ	O	B-NP	O
78	10	bioinformatics	NNS	O	I-NP	B-Jour
78	11	and	CC	O	I-NP	O
78	12	genomics	NNS	O	I-NP	B-Jour
78	13	COMMA	COMMA	O	O	O
78	14	because	IN	O	O	O
78	15	it	PRP	O	B-NP	O
78	16	sells	VBZ	O	B-VP	O
78	17	gene	NN	O	B-NP	O
78	18	targets	NNS	O	I-NP	O
78	19	along	IN	O	B-PP	O
78	20	with	IN	O	B-PP	O
78	21	information-processing	NN	O	B-NP	O
78	22	capabilities	NNS	O	I-NP	O
78	23	.	.	O	O	O

79	0	Similarly	RB	O	O	O
79	1	COMMA	COMMA	O	O	O
79	2	Compugen	NNP	O	B-NP	B-Peop
79	3	COMMA	COMMA	O	O	O
79	4	after	IN	O	B-PP	O
79	5	building	VBG	O	B-VP	O
79	6	a	DT	O	B-NP	O
79	7	successful	JJ	O	I-NP	O
79	8	business	NN	O	I-NP	O
79	9	selling	VBG	O	B-VP	O
79	10	bioinformatics	NN	O	B-NP	B-Jour
79	11	tools	NNS	O	I-NP	O
79	12	COMMA	COMMA	O	O	O
79	13	has	VBZ	O	B-VP	O
79	14	recently	RB	O	I-VP	O
79	15	added	VBD	O	I-VP	O
79	16	a	DT	O	B-NP	O
79	17	genomics	NN	O	I-NP	B-Jour
79	18	thrust	NN	O	I-NP	O
79	19	COMMA	COMMA	O	O	O
79	20	selling	VBG	O	B-VP	O
79	21	novel	NN	O	B-NP	B-Book
79	22	gene	NN	O	I-NP	O
79	23	variants	NNS	O	I-NP	O
79	24	the	DT	O	B-NP	O
79	25	Compugen	NNP	O	I-NP	O
79	26	researchers	NNS	O	I-NP	B-ProfTitle
79	27	have	VBP	O	B-VP	O
79	28	identified	VBN	O	I-VP	O
79	29	with	IN	O	B-PP	O
79	30	the	DT	O	B-NP	O
79	31	company	NN	O	I-NP	B-OrgCorp
79	32	's	POS	O	B-NP	O
79	33	tools	NNS	O	I-NP	O
79	34	.	.	O	O	O

80	0	Compared	VBN	O	B-PP	O
80	1	with	IN	O	B-PP	O
80	2	these	DT	O	B-NP	O
80	3	other	JJ	O	I-NP	O
80	4	companies	NNS	O	I-NP	B-OrgCorp
80	5	COMMA	COMMA	O	O	O
80	6	which	WDT	O	B-NP	O
80	7	have	VBP	O	B-VP	O
80	8	aimed	VBN	O	I-VP	O
80	9	for	IN	O	B-PP	O
80	10	a	DT	O	B-NP	O
80	11	corporate	JJ	O	I-NP	O
80	12	clientele	NN	O	I-NP	O
80	13	COMMA	COMMA	O	O	O
80	14	Informax	NNP	O	B-NP	B-Peop
80	15	has	VBZ	O	B-VP	O
80	16	taken	VBN	O	I-VP	O
80	17	a	DT	O	B-NP	O
80	18	vastly	RB	O	I-NP	O
80	19	different	JJ	O	I-NP	O
80	20	tack	NN	O	I-NP	O
80	21	.	.	O	O	O

81	0	For	IN	O	B-PP	O
81	1	six	CD	O	B-NP	B-Num
81	2	years	NNS	O	I-NP	B-Date
81	3	it	PRP	O	B-NP	O
81	4	has	VBZ	O	B-VP	O
81	5	sold	VBN	O	I-VP	O
81	6	a	DT	O	B-NP	O
81	7	program	NN	O	I-NP	O
81	8	for	IN	O	B-PP	O
81	9	individual	JJ	O	B-NP	O
81	10	scientists	NNS	O	I-NP	B-ProfTitle
81	11	COMMA	COMMA	O	O	O
81	12	Vector	NNP	O	B-NP	O
81	13	NTI	NNP	O	I-NP	O
81	14	COMMA	COMMA	O	O	O
81	15	which	WDT	O	B-NP	O
81	16	is	VBZ	O	B-VP	O
81	17	almost	RB	O	O	O
81	18	to	TO	O	B-PP	O
81	19	biology	NN	O	B-NP	O
81	20	what	WP	O	B-NP	O
81	21	desktop	NN	O	B-NP	O
81	22	publishing	NN	O	I-NP	O
81	23	software	NN	O	I-NP	O
81	24	was	VBD	O	B-VP	O
81	25	to	TO	O	B-VP	O
81	26	print	VB	O	I-VP	O
81	27	publications	NNS	O	B-NP	O
81	28	.	.	O	O	O

82	0	At	IN	O	B-PP	O
82	1	$3COMMA500	NN	O	B-NP	B-Money
82	2	a	DT	O	B-NP	O
82	3	user	NN	O	I-NP	O
82	4	COMMA	COMMA	O	O	O
82	5	for	IN	O	B-PP	O
82	6	the	DT	O	B-NP	O
82	7	Windows	NNP	O	I-NP	O
82	8	or	CC	O	I-NP	O
82	9	Macintosh	NNP	O	I-NP	B-OrgCorp
82	10	versions	NNS	O	I-NP	O
82	11	COMMA	COMMA	O	O	O
82	12	Vector	NNP	O	B-NP	O
82	13	NTI	NNP	O	I-NP	O
82	14	is	VBZ	O	B-VP	O
82	15	not	RB	O	O	O
82	16	inexpensive	JJ	O	O	O
82	17	.	.	O	O	O

83	0	But	CC	O	O	O
83	1	because	IN	O	O	O
83	2	it	PRP	O	B-NP	O
83	3	is	VBZ	O	B-VP	O
83	4	a	DT	O	B-NP	O
83	5	purchase	NN	O	I-NP	O
83	6	that	IN	O	B-NP	O
83	7	typically	RB	O	O	O
83	8	can	MD	O	B-VP	O
83	9	be	VB	O	I-VP	O
83	10	authorized	VBN	O	I-VP	O
83	11	at	IN	O	B-PP	O
83	12	the	DT	O	B-NP	O
83	13	department	NN	O	I-NP	O
83	14	level	NN	O	I-NP	O
83	15	COMMA	COMMA	O	O	O
83	16	it	PRP	O	B-NP	O
83	17	is	VBZ	O	B-VP	O
83	18	the	DT	O	B-NP	O
83	19	most	RBS	O	I-NP	O
83	20	widely	RB	O	O	O
83	21	used	VBN	O	O	O
83	22	bioinformatics	NN	O	B-NP	B-Jour
83	23	program	NN	O	I-NP	O
83	24	in	IN	O	B-PP	O
83	25	the	DT	O	B-NP	O
83	26	industry	NN	O	I-NP	O
83	27	.	.	O	O	O

84	0	It	PRP	O	B-NP	O
84	1	is	VBZ	O	B-VP	O
84	2	used	VBN	O	I-VP	O
84	3	at	IN	O	B-PP	O
84	4	60	CD	O	B-NP	B-Num
84	5	pharmaceuticals	NNS	O	I-NP	O
84	6	companies	NNS	O	I-NP	B-OrgCorp
84	7	COMMA	COMMA	O	O	O
84	8	250	CD	O	B-NP	B-Num
84	9	biotechnology	NN	O	I-NP	O
84	10	concerns	NNS	O	I-NP	O
84	11	and	CC	O	O	O
84	12	500	CD	O	B-NP	B-Num
84	13	academic	JJ	O	I-NP	O
84	14	institutions	NNS	O	I-NP	O
84	15	.	.	O	O	O

85	0	``	``	O	O	O
85	1	We	PRP	O	B-NP	O
85	2	've	VBP	O	B-VP	O
85	3	built	VBN	O	I-VP	O
85	4	our	PP$	O	B-NP	O
85	5	franchise	NN	O	I-NP	O
85	6	by	IN	O	B-PP	O
85	7	meeting	VBG	O	B-VP	O
85	8	the	DT	O	B-NP	O
85	9	needs	VBZ	O	B-VP	O
85	10	of	IN	O	B-PP	O
85	11	the	DT	O	B-NP	O
85	12	bench	NN	O	I-NP	O
85	13	biologistCOMMA	NN	O	I-NP	O
85	14	''	''	O	O	O
85	15	said	VBD	O	B-VP	O
85	16	Timothy	NNP	O	B-NP	B-Peop
85	17	Sullivan	NNP	O	I-NP	I-Peop
85	18	COMMA	COMMA	O	O	O
85	19	Informax	NNP	O	B-NP	O
85	20	's	POS	O	B-NP	O
85	21	senior	JJ	O	I-NP	O
85	22	vice	NN	O	I-NP	B-ProfTitle
85	23	president	NN	O	I-NP	I-ProfTitle
85	24	for	IN	O	B-PP	O
85	25	marketing	NN	O	B-NP	O
85	26	and	CC	O	I-NP	O
85	27	sales	NNS	O	I-NP	O
85	28	.	.	O	O	O

86	0	``	``	O	O	O
86	1	Informax	NNP	O	B-NP	B-Peop
86	2	took	VBD	O	B-VP	O
86	3	a	DT	O	B-NP	O
86	4	bottom-up	JJ	O	I-NP	O
86	5	approach	NN	O	I-NP	O
86	6	and	CC	O	O	O
86	7	did	VBD	O	B-VP	O
86	8	it	PRP	O	B-NP	O
86	9	well	RB	O	O	O
86	10	COMMA	COMMA	O	O	O
86	11	versus	IN	O	B-PP	O
86	12	Pangea	NNP	O	B-NP	B-Loc
86	13	and	CC	O	I-NP	O
86	14	Netgenics	NNP	O	I-NP	B-Peop
86	15	COMMA	COMMA	O	O	O
86	16	who	WP	O	B-NP	O
86	17	started	VBD	O	B-VP	O
86	18	out	IN	O	O	O
86	19	at	IN	O	B-PP	O
86	20	the	DT	O	B-NP	O
86	21	enterprise	NN	O	I-NP	O
86	22	levelCOMMA	NN	O	I-NP	O
86	23	''	''	O	O	O
86	24	he	PRP	O	B-NP	O
86	25	said	VBD	O	B-VP	O
86	26	.	.	O	O	O

87	0	Informax	NNP	O	B-NP	B-Peop
87	1	recently	RB	O	O	O
87	2	introduced	VBD	O	B-VP	O
87	3	its	PP$	O	B-NP	O
87	4	own	JJ	O	I-NP	O
87	5	enterprise	NN	O	I-NP	O
87	6	product	NN	O	I-NP	O
87	7	COMMA	COMMA	O	O	O
87	8	Software	NNP	O	B-NP	O
87	9	Solution	NN	O	I-NP	B-OrgCorp
87	10	for	IN	O	B-PP	O
87	11	Bioscience	NNP	O	B-NP	B-Loc
87	12	COMMA	COMMA	O	O	O
87	13	and	CC	O	O	O
87	14	hopes	VBZ	O	B-VP	O
87	15	to	TO	O	I-VP	O
87	16	use	VB	O	I-VP	O
87	17	the	DT	O	B-NP	O
87	18	leverage	NN	O	I-NP	O
87	19	of	IN	O	B-PP	O
87	20	its	PP$	O	B-NP	O
87	21	existing	VBG	O	I-NP	O
87	22	customer	NN	O	I-NP	O
87	23	base	NN	O	I-NP	O
87	24	to	TO	O	B-VP	O
87	25	win	VB	O	I-VP	O
87	26	sales	NNS	O	B-NP	O
87	27	at	IN	O	B-PP	O
87	28	large	JJ	O	B-NP	O
87	29	companies	NNS	O	I-NP	B-OrgCorp
87	30	.	.	O	O	O

88	0	-LBR-	-LBR-	O	O	O
88	1	END	NNP	O	O	B-Org
88	2	OPTIONAL	NNP	O	O	I-Org
88	3	TRIM	NNP	O	O	I-Org
88	4	-RBR-	-RBR-	O	O	O

89	0	One	CD	O	B-NP	B-Num
89	1	hurdle	NN	O	I-NP	O
89	2	for	IN	O	B-PP	O
89	3	all	DT	O	B-NP	O
89	4	of	IN	O	B-PP	O
89	5	these	DT	O	B-NP	O
89	6	competitors	NNS	O	I-NP	O
89	7	is	VBZ	O	B-VP	O
89	8	that	IN	O	O	O
89	9	the	DT	O	B-NP	O
89	10	large	JJ	O	I-NP	O
89	11	companies	NNS	O	I-NP	B-OrgCorp
89	12	that	WDT	O	B-NP	O
89	13	are	VBP	O	B-VP	O
89	14	their	PP$	O	O	O
89	15	obvious	JJ	O	B-NP	O
89	16	customers	NNS	O	I-NP	O
89	17	often	RB	O	O	O
89	18	have	VBP	O	B-VP	O
89	19	substantial	JJ	O	B-NP	O
89	20	bioinformatics	NN	O	I-NP	B-Jour
89	21	capabilities	NNS	O	I-NP	O
89	22	of	IN	O	B-PP	O
89	23	their	PP$	O	B-NP	O
89	24	own	JJ	O	I-NP	O
89	25	_	NN	O	I-NP	O
89	26	expertise	NN	O	I-NP	O
89	27	that	IN	O	B-NP	O
89	28	the	DT	O	B-NP	O
89	29	company	NN	O	I-NP	B-OrgCorp
89	30	may	MD	O	B-VP	O
89	31	even	VB	O	I-VP	O
89	32	view	VB	O	I-VP	O
89	33	as	IN	O	B-PP	O
89	34	a	DT	O	B-NP	O
89	35	proprietary	JJ	O	I-NP	O
89	36	advantage	NN	O	I-NP	O
89	37	.	.	O	O	O

90	0	``	``	O	O	O
90	1	You	PRP	O	B-NP	O
90	2	're	VBP	O	B-VP	O
90	3	trying	VBG	O	I-VP	O
90	4	to	TO	O	I-VP	O
90	5	do	VB	O	I-VP	O
90	6	cutting-edge	JJ	O	B-NP	O
90	7	research	NN	O	I-NP	O
90	8	COMMA	COMMA	O	O	O
90	9	and	CC	O	O	O
90	10	if	IN	O	O	O
90	11	you	PRP	O	B-NP	O
90	12	're	VBP	O	B-VP	O
90	13	on	IN	O	B-PP	O
90	14	the	DT	O	B-NP	O
90	15	leading	VBG	O	I-NP	O
90	16	edge	NN	O	I-NP	O
90	17	of	IN	O	B-PP	O
90	18	the	DT	O	B-NP	O
90	19	curve	NN	O	I-NP	B-Medical
90	20	that	WDT	O	B-NP	O
90	21	means	VBZ	O	B-VP	O
90	22	you	PRP	O	B-NP	O
90	23	also	RB	O	O	O
90	24	have	VBP	O	B-VP	O
90	25	to	TO	O	I-VP	O
90	26	develop	VB	O	I-VP	O
90	27	the	DT	O	B-NP	O
90	28	software	NN	O	I-NP	O
90	29	to	TO	O	B-VP	O
90	30	do	VB	O	I-VP	O
90	31	itCOMMA	NN	O	B-NP	O
90	32	''	''	O	O	O
90	33	said	VBD	O	B-VP	O
90	34	Paul	NNP	O	B-NP	B-Peop
90	35	Godowski	NNP	O	I-NP	I-Peop
90	36	COMMA	COMMA	O	O	O
90	37	director	NN	O	B-NP	B-ProfTitle
90	38	of	IN	O	B-PP	O
90	39	molecular	JJ	O	B-NP	B-Jour
90	40	biology	NN	O	I-NP	I-Jour
90	41	at	IN	O	B-PP	O
90	42	Genentech	NNP	O	B-NP	B-OrgCorp
90	43	Inc.	NNP	O	I-NP	O
90	44	COMMA	COMMA	O	O	O
90	45	the	DT	O	B-NP	O
90	46	pioneering	JJ	O	I-NP	O
90	47	biotech	NN	O	I-NP	O
90	48	company	NN	O	I-NP	B-OrgCorp
90	49	.	.	O	O	O

91	0	``	``	O	O	O
91	1	On	IN	O	B-PP	O
91	2	the	DT	O	B-NP	O
91	3	other	JJ	O	I-NP	O
91	4	hand	NN	O	I-NP	O
91	5	COMMA	COMMA	O	O	O
91	6	there	EX	O	B-NP	O
91	7	are	VBP	O	B-VP	O
91	8	products	NNS	O	B-NP	O
91	9	out	IN	O	O	O
91	10	there	RB	O	B-NP	O
91	11	from	IN	O	B-PP	O
91	12	these	DT	O	B-NP	O
91	13	third-party	JJ	O	I-NP	O
91	14	vendors	NNS	O	I-NP	O
91	15	we	PRP	O	B-NP	O
91	16	can	MD	O	B-VP	O
91	17	import	VB	O	I-VP	O
91	18	for	IN	O	B-PP	O
91	19	our	PP$	O	B-NP	O
91	20	programsCOMMA	NN	O	I-NP	O
91	21	''	''	O	I-NP	O
91	22	Godowski	NNP	O	I-NP	O
91	23	.	.	O	O	O

92	0	``	``	O	O	O
92	1	It	PRP	O	B-NP	O
92	2	's	VBZ	O	B-VP	O
92	3	a	DT	O	B-NP	O
92	4	mixture	NN	O	I-NP	O
92	5	COMMA	COMMA	O	O	O
92	6	and	CC	O	O	O
92	7	I	PRP	O	B-NP	O
92	8	don	VB	O	B-VP	O
92	9	't	NN	O	B-NP	O
92	10	see	VBP	O	B-VP	O
92	11	that	IN	O	O	O
92	12	going	VBG	O	B-VP	O
92	13	away	RB	O	O	O
92	14	COMMA	COMMA	O	O	O
92	15	certainly	RB	O	O	O
92	16	not	RB	O	O	O
92	17	at	IN	O	B-PP	O
92	18	a	DT	O	B-NP	O
92	19	place	NN	O	I-NP	O
92	20	like	IN	O	B-PP	O
92	21	Genentech	NNP	O	B-NP	B-OrgCorp
92	22	.	.	O	O	O
92	23	''	''	O	O	O

93	0	No	DT	O	O	O
93	1	wonder	VBP	O	B-VP	O
93	2	Pangea	NNP	O	B-NP	B-Loc
93	3	is	VBZ	O	B-VP	O
93	4	looking	VBG	O	I-VP	O
93	5	to	TO	O	B-PP	O
93	6	cyberspace	NN	O	B-NP	O
93	7	to	TO	O	B-VP	O
93	8	expand	VB	O	I-VP	O
93	9	its	PP$	O	B-NP	O
93	10	potential	JJ	O	I-NP	O
93	11	audience	NN	O	I-NP	O
93	12	.	.	O	O	O

94	0	``	``	O	O	O
94	1	Only	RB	O	B-NP	O
94	2	a	DT	O	I-NP	O
94	3	few	JJ	O	I-NP	O
94	4	select	VBP	O	B-VP	O
94	5	pharmas	NNS	O	B-NP	O
94	6	can	MD	O	B-VP	O
94	7	afford	VB	O	I-VP	O
94	8	the	DT	O	B-NP	O
94	9	tools	NNS	O	I-NP	O
94	10	COMMA	COMMA	O	O	O
94	11	and	CC	O	O	O
94	12	if	IN	O	O	O
94	13	they	PRP	O	B-NP	O
94	14	can	MD	O	B-VP	O
94	15	COMMA	COMMA	O	O	O
94	16	then	RB	O	O	O
94	17	in	IN	O	B-PP	O
94	18	some	DT	O	B-NP	O
94	19	cases	NNS	O	I-NP	O
94	20	they	PRP	O	B-NP	O
94	21	can	MD	O	B-VP	O
94	22	also	RB	O	I-VP	O
94	23	afford	VB	O	I-VP	O
94	24	to	TO	O	I-VP	O
94	25	produce	VB	O	I-VP	O
94	26	their	PP$	O	B-NP	O
94	27	own	JJ	O	I-NP	O
94	28	softwareCOMMA	NN	O	I-NP	O
94	29	''	''	O	I-NP	O
94	30	Couch	NNP	O	I-NP	B-Peop
94	31	said	VBD	O	B-VP	O
94	32	.	.	O	O	O

95	0	``	``	O	O	O
95	1	Why	WRB	O	O	O
95	2	not	RB	O	O	O
95	3	take	VB	O	B-VP	O
95	4	the	DT	O	B-NP	O
95	5	infrastructure	NN	O	I-NP	O
95	6	we	PRP	O	B-NP	O
95	7	've	VBP	O	B-VP	O
95	8	created	VBN	O	I-VP	O
95	9	COMMA	COMMA	O	O	O
95	10	add	VBP	O	B-VP	O
95	11	a	DT	O	B-NP	O
95	12	graphic	JJ	O	I-NP	O
95	13	interface	NN	O	I-NP	O
95	14	that	DT	O	B-NP	O
95	15	makes	VBZ	O	B-VP	O
95	16	it	PRP	O	B-NP	O
95	17	easier	JJR	O	O	O
95	18	COMMA	COMMA	O	O	O
95	19	and	CC	O	O	O
95	20	offer	VBP	O	B-VP	O
95	21	it	PRP	O	B-NP	O
95	22	directly	RB	O	O	O
95	23	to	TO	O	B-PP	O
95	24	the	DT	O	B-NP	O
95	25	scientist	NN	O	I-NP	B-ProfTitle
95	26	?	.	O	O	O

96	0	We	PRP	O	B-NP	O
96	1	are	VBP	O	B-VP	O
96	2	taking	VBG	O	I-VP	O
96	3	the	DT	O	B-NP	O
96	4	Internet	NN	O	I-NP	B-OrgCorp
96	5	COMMA	COMMA	O	O	O
96	6	which	WDT	O	B-NP	O
96	7	was	VBD	O	B-VP	O
96	8	originally	RB	O	I-VP	O
96	9	developed	VBN	O	I-VP	O
96	10	to	TO	O	I-VP	O
96	11	do	VB	O	I-VP	O
96	12	research	NN	O	B-NP	O
96	13	COMMA	COMMA	O	O	O
96	14	and	CC	O	O	O
96	15	giving	VBG	O	B-VP	O
96	16	it	PRP	O	B-NP	O
96	17	back	RB	O	O	O
96	18	to	TO	O	B-PP	O
96	19	the	DT	O	B-NP	O
96	20	researchers	NNS	O	I-NP	B-ProfTitle
96	21	.	.	O	O	O
96	22	''	''	O	O	O

97	0	&	CC	O	O	O
97	1	QL	NNP	O	B-NP	O
97	2	;	:	O	O	O
97	3	NYT-09-19-99	NNP	O	B-NP	O
97	4	1641EDT	NN	O	I-NP	B-Num
97	5	&	CC	O	O	O
97	6	QL	NNP	O	B-NP	O
97	7	;	:	O	O	O
